0000950170-24-036624 | 10-K | XBRL Viewer

Income Taxes

12 Months Ended

Dec. 31, 2023

Note 12. Income Taxes

Teknova’s benefit from income taxes consist of the following (in thousands):


	For the Year Ended December 31,
	2023			2022
Current:
Federal	$	—		$	—
State		6			7
Total current		6			7
Deferred:
Federal		(25	)		(2,055	)
State		(279	)		125
Total deferred		(304	)		(1,930	)
Income tax benefit	$	(298	)	$	(1,923	)

A reconciliation of the statutory tax rate to the Company’s effective tax rate is as follows:


	For the Year Ended December 31,
	2023			2022
Statutory federal income tax rate %		21.0	%		21.0	%
State income tax rate		5.9			5.6
Stock compensation		(0.5	)		(0.5	)
Research and development credit		0.7			0.2
Change in valuation allowance		(26.1	)		(13.6	)
Goodwill impairment		—			(9.0	)
Other		(0.2	)		0.2
Effective tax rate %		0.8	%		3.9	%

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due, plus deferred taxes. Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will be either deductible or taxable when the assets and liabilities are recovered or settled. The Company’s component of net deferred tax liability and assets consist of the following (in thousands):


	As of December 31,
	2023			2022
Deferred tax asset
Net operating loss carryforwards	$	14,184		$	8,005
Accrued compensation		803			552
Stock compensation		1,823			1,008
Tax credit carryforwards		880			275
Accruals and other		131			321
Operating lease liabilities		4,599			5,435
Capitalized research and development expenses		2,304			1,450
Inventory capitalization		428			—
Total deferred tax asset		25,152			17,046
Deferred tax liability
Property, plant, and equipment		(1,231	)		(1,131	)
Intangibles		(3,600	)		(4,693	)
Operating right-of-use lease assets		(4,402	)		(5,275	)
Total deferred tax liability		(9,233	)		(11,099	)
Valuation allowance		(16,838	)		(7,170	)
Net deferred tax liability	$	(919	)	$	(1,223	)

As of the end of December 31, 2023, Teknova has federal and state net operating loss carryforwards (NOLs) of $50.2 million and $53.6 million, respectively. The federal NOLs will carryforward indefinitely but are subject to an 80% taxable income limitation. The state NOLs begin to expire in 2036. As of December 31, 2023, the Company has federal research and development tax credit carryforwards of $0.6 million, which will begin to expire in 2036 and a state research and development tax credit carryforward of $0.2 million and carry forward indefinitely. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. This could limit the amount of NOLs and tax credits that the Company can utilize annually to offset future taxable income or tax liabilities.

For the years ended December 31, 2023 and December 31, 2022, the Company recorded a net increase in valuation allowances of $9.7 million and $6.7 million, respectively, comprised primarily of an increase of valuation allowance on certain NOLs being carried forward which are not expected to be realizable. Valuation allowances are determined based on management’s assessment of its deferred tax assets that are more likely than not to be realized.

The Company had unrecognized tax benefits of $0.1 million at December 31, 2023 and an insignificant amount at December 31, 2022. In connection with FASB’s Accounting for Uncertainty in Income Taxes, the Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not expect to recognize any unrecognized tax benefits over the next twelve months. Consequently, the Company has not accrued interest or penalties related to uncertain tax positions as of the end of December 31, 2023 or 2022.

Teknova files income tax returns in the U.S. federal jurisdiction and various states. The Company is no longer subject to U.S. federal income tax examinations for tax years prior to 2020. The Company is no longer subject to state income tax examinations for tax years prior to 2019. All net operating losses and tax credits generated to date are subject to adjustment for U.S. federal and state income tax purposes. The Company is currently not under examination by the Internal Revenue Service or any other taxing authorities.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Net Loss Per Share - Summary of Common Stock Equivalents Excluded from Calculation of Diluted Loss per Share Attributable to Common Stockholders (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Employee share-based awards to purchase common stock	4,009,699	3,208,403

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Accrued Liabilities, Current [Abstract]

Summary of Accrued Liabilities

Accrued liabilities were comprised of the following (in thousands):


	As of December 31,
	2023		2022
Payroll-related	$	3,826	$	2,796
Property, plant, and equipment		—		1,966
Deferred revenue		16		198
Insurance premiums and accrued interest		409		—
Loss contingency accrual		300		—
Other		1,028		1,243
Total current accrued liabilities	$	5,579	$	6,203

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 36,684	$ 41,420
Cost of sales	26,388	23,944
Gross profit	10,296	17,476
Operating expenses:
Research and development	5,567	7,737
Sales and marketing	9,330	9,151
General and administrative	25,450	28,298
Amortization of intangible assets	1,148	1,148
Goodwill impairment	0	16,613
Tradename impairment	2,169	0
Long-lived assets impairment	2,195	4,188
Total operating expenses	45,859	67,135
Loss from operations	(35,563)	(49,659)
Other (expenses) income, net
Interest (expense) income, net	(833)	213
Other income, net	142	55
Loss on extinguishment of debt	(824)	0
Total other (expenses) income, net	(1,515)	268
Loss before income taxes	(37,078)	(49,391)
Benefit from income taxes	(298)	(1,923)
Net loss	$ (36,780)	$ (47,468)
Earnings Per Share [Abstract]
Basic	$ (1.16)	$ (1.69)
Diluted	$ (1.16)	$ (1.69)
Weighted Average Number of Shares Outstanding, Basic and Diluted [Abstract]
Basic	31,819,776	28,083,563
Diluted	31,819,776	28,083,563

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net income (loss)	$ (36,780)	$ (47,468)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Bad debt expense	21	25
Inventory reserve	323	697
Depreciation and amortization	5,660	3,165
Stock-based compensation	4,137	3,711
Deferred taxes	(304)	(1,930)
Amortization of debt financing costs	498	278
Non-cash lease expense	137	329
Loss on disposal of property, plant, and equipment	57	326
Goodwill impairment	0	16,613
Tradename impairment	2,169	0
Long-lived assets impairment	2,195	4,188
Loss on extinguishment of debt	824	0
Changes in operating assets and liabilities:
Accounts receivable	292	380
Inventories	330	(7,550)
Income taxes receivable	22	1,166
Prepaid expenses and other current assets	131	64
Other non-current assets	400	(2,072)
Accounts payable	(773)	572
Accrued liabilities	1,936	188
Other	(89)	(82)
Cash used in operating activities	(18,814)	(27,400)
Investing activities:
Proceeds from sale of property, plant, and equipment	197	0
Purchase of property, plant and equipment	(7,934)	(28,149)
Cash used in investing activities	(7,737)	(28,149)
Financing activities:
Proceeds from equity financing, net	22,503	0
Repayment of long-term debt	(10,000)	0
Proceeds from financed insurance premiums	1,004	0
Repayment of financed insurance premiums	(594)	0
Proceeds from long-term debt	0	10,135
Payment of debt issuance costs	(47)	(172)
Payment of exit fee costs	0	(135)
Payment of at-the-market facility costs	(395)	0
Proceeds from exercise of stock options	76	145
Proceeds from issuance of common stock under employee stock purchase plan	252	294
Cash provided by financing activities	12,799	10,267
Change in cash and cash equivalents	(13,752)	(45,282)
Cash and cash equivalents at beginning of period	42,236	87,518
Cash and cash equivalents at end of period	28,484	42,236
Supplemental cash flow disclosures:
Income taxes paid	0	0
Interest paid, net of amounts capitalized	1,749	101
Capitalized property, plant and equipment included in accounts payable and accrued liabilities	51	2,237
Offering costs included in accounts payable	37	0
Recognition of operating right-of-use lease asset	(1,137)	22,094
Recognition of operating lease liabilities	$ (1,193)	$ 22,363

Leases (Additional Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating lease expense	$ 2.9	$ 3.2
Lease liabilities cash paid	$ 2.8	$ 2.8
Weighted-average discount rate	5.00%
Weighted-average remaining lease term	8 years 10 months 24 days
Maximum [Member]
Remaining lease terms	14 years
Minimum [Member]
Remaining lease terms	1 year

Net Loss Per Share

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Net Loss Per Share

Note 13. Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents to the extent they are dilutive. For purposes of this calculation, stock options, restricted stock units, and employee stock purchase rights are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):


	For the Year Ended December 31,
	2023			2022
Net loss	$	(36,780	)	$	(47,468	)
Weighted average shares used in computing net loss per share—basic and diluted		31,819,776			28,083,563
Net loss per share—basic and diluted	$	(1.16	)	$	(1.69	)

The following is a summary of the common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive:


	For the Year Ended December 31,
	2023		2022
Employee share-based awards to purchase common stock		4,009,699		3,208,403

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Income tax rate, percent	0.80%	3.90%
Net increase decrease in valuation allowances	$ 9,700,000	$ 6,700,000
Unrecognized Tax Benefits	136,000	42,000	$ 0
Accrued interest or penalties	0	$ 0
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 50,200,000
Taxable income limitation, percent	80.00%
Federal [Member] \| Research and Development Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Research and development tax credit carryforwards	$ 600,000
Research and development tax credit carryforwards expiration year	2036
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 53,600,000
Net operating loss carryforwards expiration year	2036
State [Member] \| Research and Development Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	$ 200,000

Income Taxes - Summary of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current:
Federal	$ 0	$ 0
State	6	7
Total current	6	7
Deferred:
Federal	(25)	(2,055)
State	(279)	125
Total deferred	(304)	(1,930)
Income tax benefit	$ (298)	$ (1,923)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Revenue Recognition

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Revenue

Note 3. Revenue Recognition

Teknova has two primary product categories: Lab Essentials and Clinical Solutions.

Lab Essentials

Teknova is a leader in providing highly complex chemical formulations for use in biological research and drug discovery. The Company's core research products consist of commonly used, catalog solutions and customer-specified formulations. During discovery, the Company's products are used regularly in small, bench-scale experiments. As customers optimize their processes and begin to scale up in volume, they tend to order more custom products. The Lab Essentials portion of Teknova's business includes: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova's Lab Essentials products include essential formulations for common research applications and highly customized formulations for customer-specific applications in genomics and bioproduction.

Clinical Solutions

Teknova is ISO 13485:2016 certified, enabling the Company to meet the quality system regulation of products for use as components in diagnostic and therapeutic products manufactured by the Company's customers. Teknova believes that its Clinical Solutions products are used in the production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The Clinical Solutions portion of our business includes: liquid cell culture media and supplements for cellular expansion and molecular biology reagents for sample manipulation, resuspension, and purification.

Teknova’s revenue, disaggregated by product category, was as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
Lab Essentials	$	28,800	$	31,772
Clinical Solutions		6,738		8,445
Other		1,146		1,203
Total revenue	$	36,684	$	41,420

Teknova’s revenue, disaggregated by geographic region, was as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
United States	$	35,000	$	40,103
International		1,684		1,317
Total revenue	$	36,684	$	41,420

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

Intangible Assets, Net - Summary of Intangible Assets with Definite and Indefinite Lives (Details) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Intangible Assets [Line Items]

Intangible Assets, Gross

$ 19,930

$ 22,099

Intangible Assets, Net

14,239

17,556

Finite-Lived Intangible Assets, Accumulated Amortization

5,691

4,543

Customer Relationships [Member]

Intangible Assets [Line Items]

Intangible Assets, Net

3,489

4,637

Finite-Lived Intangible Assets, Gross

9,180

Finite-Lived Intangible Assets, Accumulated Amortization

5,691

4,543

Trade Names [Member]

Intangible Assets [Line Items]

Intangible Assets, Net

^[1]

10,750

12,919

Indefinite-Lived Intangible Assets, Gross

^[1]

10,750

12,919

Indefinite-Lived Intangible Assets, Accumulated Amortization

^[1]

$ 0

[1]	(1) During the year ended December 31, 2023, a charge of $2.2 million was recorded on our indefinite lived tradename asset as such to reflect the impairment of the value ascribed to the indefinite lived tradename asset.

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Payroll-related	$ 3,826	$ 2,796
Property, plant and equipment	0	1,966
Deferred revenue	16	198
Insurance premiums and accrued interest	409	0
Loss contingency accrual	300	0
Other	1,028	1,243
Total current accrued liabilities	$ 5,579	$ 6,203	$ 5,579

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Schedule of Computation of Basic And Diluted Net (Loss) Income Per Share Attributable to Common Stockholders

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):


	For the Year Ended December 31,
	2023			2022
Net loss	$	(36,780	)	$	(47,468	)
Weighted average shares used in computing net loss per share—basic and diluted		31,819,776			28,083,563
Net loss per share—basic and diluted	$	(1.16	)	$	(1.69	)

Summary of Common Stock Equivalents Excluded from Calculation of Diluted Loss per Share Attributable to Common Stockholders


	For the Year Ended December 31,
	2023		2022
Employee share-based awards to purchase common stock		4,009,699		3,208,403

Concentrations of Risk (Tables)

12 Months Ended

Dec. 31, 2023

Fair Value, Concentration of Risk, Financial Assets, Balance Sheet Groupings [Abstract]

Summary Of Company Revenues And Outstanding Balance Of Accounts Receivable

Customers who accounted for 10% or more of the Company's revenues and outstanding balance of accounts receivable are presented as follows:


	For the Year Ended December 31,		As of December 31,
	2023	2022	2023	2022
Distributor customer A	18%	15%	16%	17%
Distributor customer B	*	*	*	15%

* Represents less than 10%.

Summary Of Company Inventory Purchases And Outstanding Balance Of Accounts Payable

Suppliers who accounted for 10% or more of the Company's inventory purchases and outstanding balance of accounts payable are presented as follows:


	For the Year Ended December 31,		As of December 31,
	2023	2022	2023	2022
Distributor supplier A	40%	37%	18%	11%
Direct supplier A	*	14%	*	*
Direct supplier B	*	12%	*	*
Direct supplier C	10%	*	*	*

* Represents less than 10%.

Concentrations of Risk - Summary of revenues and outstanding balance of accounts receivable (Details) - Customers Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
SalesRevenueNetMember \| Distributor customer A [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration Risk, Percentage	18.00%	15.00%
Accounts Receivable [Member] \| Distributor customer A [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration Risk Percentage	16.00%	17.00%
Accounts Receivable [Member] \| Direct customer B [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration Risk Percentage		15.00%

Other Financial Information - Change in unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Uncertainties [Abstract]
Beginning balance	$ 42	$ 0
Tax positions related to the current year:
Additions	86	42
Reductions	0	0
Tax positions related to the prior year:
Additions	8	0
Reductions	0	0
Ending balance	$ 136	$ 42

Summary of Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Basis of Presentation and Use of Estimates

Basis of Accounting, Presentation, and Use of Estimates

The accompanying financial statements and related notes are prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain amounts of assets and liabilities, and disclosures of assets and liabilities, at the date of each financial statement, and the reported amount of revenues and expenses

during the reporting period. Significant items that are subject to such estimates and assumptions include, but are not limited to, the revenue recognition, impairment of long-lived assets and intangible assets, valuation of share-based payment awards, and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions.

Going Concern

Accounting Standards Codification (ASC) 205-40, Presentation of Financial Statements—Going Concern, requires management to evaluate an entity’s ability to continue as a going concern for the twelve-month period following the date on which the financial statements are available for issuance. Management performed an assessment to determine whether there were conditions or events that, considered individually and in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying financial statements are being issued. This assessment indicated certain negative conditions and events, described further below, that raise substantial doubt about the Company’s ability to continue as a going concern.

As of December 31, 2023, the Company had limited capital resources to fund ongoing operations. During the year ended December 31, 2023, Teknova incurred net losses of $36.8 million. In addition, as of December 31, 2023, the Company had an accumulated deficit of $91.8 million and a total principal amount of outstanding borrowings of $12.1 million. As of December 31, 2023, the Company had $36.8 million of working capital, which included $28.5 million in cash and cash equivalents. The Company’s available capital resources may not be sufficient for the Company to continue to meet its obligations as they become due over the next twelve months if the Company cannot improve its operating results or increase its operating cash inflows. If these capital resources are not sufficient, the Company may need to raise additional capital through the sale of equity or debt securities, enter into strategic business collaboration agreements with other companies, seek other funding facilities, or sell assets. However, there can be no assurance that the Company will be able to accomplish any of the foregoing or do so on favorable terms. If the Company is unable to meet its obligations when they become due over the next twelve months through its available capital resources, or obtain new sources of capital when needed, the Company may have to delay expenditures, reduce the scope of its manufacturing operations, reduce or eliminate one or more of its development programs, make significant changes to its operating plan, or cease its operations.

As disclosed in Note. 17. Subsequent Events, the Company is subject to certain financial covenants as set forth in the Amended Credit Agreement (defined in Note 17). These financial covenants include (i) a trailing twelve months minimum net revenue covenant that must be met each calendar month, and (ii) a requirement to maintain a minimum level of cash at all times through the term of the Amended Credit Agreement. To the extent the Company continues to experience unfavorable market conditions, like other companies in the industry, the Company believes it may be unable to comply with the trailing twelve months revenue covenant during the twelve-month period following the date on which the financial statements are available for issuance. Failing to comply with the monthly revenue covenant would be an event of default under the Amended Credit Agreement and the lender would have the right, but not the obligation, to accelerate the Company’s obligations to pay the outstanding balance due and payable under the Term Loan (defined in Note 10). If the Company violates one or more of its covenants under the Amended Credit Agreement and is not able to obtain a waiver from or agree to an accommodation with the lender with respect to any such violation, the Company could be required to pay all or a portion of the outstanding amount under the Term Loan. In that event, the Company may need to seek other sources of capital and there can be no assurances that the Company would be able to do so on acceptable terms.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and the satisfaction of liabilities in the normal course of business for one year following the issuance of these audited financial statements. As such, the accompanying financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.

Segment Reporting

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. Teknova’s CODM is its Chief Executive Officer, currently Stephen Gunstream. Teknova has determined that it operates in one reporting unit, one operating segment, and one reportable segment, as the CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.

Concentrations of Credit Risk

Teknova’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places its cash with high-quality banking institutions. At times, the Company’s cash balances may exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Teknova’s cash equivalents consist primarily of money market funds and U.S. Treasuries. Teknova extends credit to customers based on its evaluation of the customer’s financial condition and routinely communicates with its customers regarding payments. The Company has a history of limited write-offs, and therefore believes that its accounts receivable credit risk exposure is low. For information regarding the Company’s significant customers and suppliers, see Note 4. Concentrations of Risk.

Cash and Cash Equivalents

Teknova’s cash and cash equivalents include cash on hand, cash held in banks, and highly-liquid investments with maturities of three months or less at the date of acquisition. Teknova maintains its cash in bank deposit accounts in financial institutions that are insured by the FDIC up to a balance of $250.0 thousand. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.

Fair Value of Financial Instruments

The carrying amounts of certain of Teknova’s financial instruments, including cash equivalents, accounts receivable, inventories, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities.

Accounts Receivable

Accounts receivable are stated at invoice value, less estimated allowances for doubtful accounts. Teknova uses the allowance method to account for uncollectible accounts receivable, calculated by management using the historical average of uncollectible accounts. The Company continually monitors its customer payments and maintains an allowance for estimated losses resulting from its customers’ inability to make required payments. Accounts receivable are considered past due once customer payment terms have been exceeded. Receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded when received.

Inventories

Inventory, consisting of raw materials, work in process and finished goods, is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Teknova writes down its inventory for estimated obsolescence or inventory in excess of reasonably expected near-term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated net realizable value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by Teknova, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory, and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.

Capitalized Software Implementation Costs

Teknova capitalizes certain implementation costs incurred under a cloud computing hosting arrangement. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within other assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the expected term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. As of December 31, 2023 and 2022, Teknova had capitalized software implementation costs of $1.8 million and $2.2 million, respectively, which were included within other non-current assets in the accompanying financial statements. Amortization expense related to capitalized implementation costs for the years ended December 31, 2023 and 2022 were $0.4 million and $0.1 million, respectively, which were included within operating expenses in the accompanying financial statements.

Property, Plant and Equipment

Property, Plant, and Equipment

Teknova records property, plant, and equipment at fair value when it is acquired in a business combination or at cost for all other purchases of property, plant, and equipment. Property, plant, and equipment is depreciated over the estimated useful lives of the assets, using the straight-line method. Any leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful life of the asset or the estimated remaining life of the lease. Costs for repairs and maintenance that do not significantly increase the value or estimated lives of property, plant, and equipment are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheets, and the resulting gain or loss is reflected in the statements of operations.

The estimated useful lives of the major classes of property and equipment are as follows:


		Estimated Useful Lives
Machinery and equipment		5 – 15 years
Office furniture and equipment		3 – 7 years
Vehicles		5 years
Leasehold improvements		3 – 15 years

Impairment of Long-Lived Assets

Teknova evaluates its long-lived assets for impairment when events or changes in circumstances indicate a possible inability to recover carrying amounts. Recoverability is assessed by comparing the carrying value of the assets to estimated undiscounted future cash flows expected to be generated by the assets. Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated during the life of those assets are less than the assets’ carrying amounts. If an asset is impaired, the loss is measured as the amount by which the asset’s carrying value exceeds its fair value. For each of the years ended December 31, 2023 and 2022, the Company recorded impairments of its long-lived assets, see Note 6. Property, Plant, and Equipment, Net.

Intangible Assets

Teknova’s intangible assets consist of the Teknova trade name and the Company’s customer relationships.

Indefinite lived intangible assets are not amortized but are tested for impairment at least annually as of October 1, or more frequently if events or circumstances indicate that it is more likely than not that an asset is impaired. If the fair value of the asset is less than its carrying amount, an impairment charge would be recognized in an amount equal to the difference between the carrying amount and the fair value.

Finite-lived intangible assets are amortized over the estimated economic useful lives of the assets, which is the period during which expected cash flows support the fair value of such intangible assets. Teknova reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or an asset group may not be recoverable. When such an event occurs, management determines

whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the related assets’ or asset group’s carrying value.

During the year ended December 31, 2023, the Company impaired its indefinite lived intangible asset. See Note 8. Intangible Assets, Net. During the year ended December 31, 2022, the Company fully impaired its goodwill, see Note 8. Intangible Assets, Net. No other intangible assets were impaired during the year ended December 31, 2023 and 2022.

Leases

The Company determines if an arrangement is an operating lease at a lease’s inception. Leases with an initial term of 12 months or fewer are not recorded on the balance sheet. All other operating leases are recorded on the balance sheet with a corresponding operating lease asset, net, representing the right to use the underlying asset for the lease term and the operating lease liabilities representing the obligation to make lease payments arising from the lease. The Company’s lease agreements do not contain any material residual value guarantees or restrictive covenants.

Operating lease assets and operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the lease when such options are reasonably certain to be exercised. The present value of lease payments is determined primarily using the incremental borrowing rate, adjusted for the lease term, based on the information available at the lease commencement or modification date as required. Lease agreements with lease and non-lease components are generally accounted for as a single lease component. The Company’s operating lease expense is recognized on a straight-line basis over the lease term.

Debt Issuance Costs

Debt issuance costs represent legal, consulting, and other financial costs associated with debt financing and are presented on the balance sheets as a direct reduction from the carrying amount of the related debt instrument. Debt issuance costs on the term debt are amortized to interest expense over the term of the applicable debt agreement using the effective interest rate method.

Revenue Recognition

We account for revenue in accordance with ASC 606, Revenue From Contracts With Customers. Teknova recognizes revenue for sales of goods through the following steps:

▪

Identification of the contract, or contracts, with a customer, typically a purchase order

▪

Identification of the performance obligations in the contract

▪

Determination of the transaction price

▪

Allocation of the transaction price to the performance obligations in the contract

▪

Recognition of revenue when, or as, the company satisfies a performance obligation

Teknova recognizes revenue from the sale of manufactured products and services when the Company transfers control of promised goods or services to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Control is transferred when the customer has the ability to direct the use of and obtain benefits from the goods or services. The majority of the Company’s sales agreements contain performance obligations satisfied at a point in time when control is transferred to the customer.

Teknova’s sales are made directly to customers or through distributors, generally under agreements with payment terms typically shorter than 90 days and, in no case exceeding one year. Therefore, Teknova’s contracts do not contain a significant financing component. Sales, value add, and other taxes collected concurrent with revenue are excluded from sales. The Company records amounts billed to customers for shipping and handling in a sales transaction as revenue. Shipping and handling costs are included in general and administrative expenses as revenue

is recognized. Shipping and handling costs for the years ended December 31, 2023 and 2022 were $1.2 million and $1.4 million, respectively.

Occasionally, Teknova offers rebates, discounts, and returns on its products, however returns and refunds occur rarely. The Company records rebates, discounts, and returns at the time they occur. The difference between recording these as they occur and estimating the amount of consideration in exchange for the transfer of promised goods would not have a material impact on the financial statements.

Costs incurred to obtain contracts with customers are expensed immediately, because the amortization period for such costs is one year or less.

Cost of Sales

Cost of sales includes salaries, wages and benefits, raw materials consumption (including direct and indirect material), depreciation, utilities, rent, manufacturing supplies, and other production overhead.

Research and Development Expenses

The Company’s research and development expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel in process engineering and product development functions, expenses related to occupancy costs, laboratory supplies, consulting fees, and depreciation associated with various assets used in the research and development of the Company’s products and processes.

Sales and Marketing Expenses

The Company’s sales and marketing expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for sales and marketing employees, expenses related to occupancy costs, brand strategy, website, content, and collateral. The Company expenses advertising costs as incurred. Advertising expenses are included in sales and marketing expenses in the accompanying financial statements. Advertising expenses were $0.1 million and not significant in the years ended December 31, 2023 and 2022, respectively.

General and Administrative Expenses

The Company’s general and administrative expenses primarily consist of costs associated with executive and administrative staff, and other expenses such as shipping charges, professional service fees, occupancy costs, IT systems, insurance, depreciation, and stock-based compensation expense for executive and administrative staff

Reduction in Workforce

On February 1, 2023, the Company carried out a reduction in workforce of approximately 40 positions, aimed at reducing operating expenses. The Company incurred $0.7 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2023, in general and administrative expenses in the accompanying financial statements.

At-the-Market Facility Policy Text Block

At-the-Market Facility

On March 30, 2023, the Company entered into a sales agreement (the ATM Facility) with Cowen and Company, LLC (Cowen), under which the Company may offer and sell, from time to time, shares of its common stock having aggregate gross proceeds of up to $50.0 million. The issuance and sale of these shares pursuant to the ATM Facility are deemed “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the Securities Act), and are registered under the Securities Act. The Company will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the ATM Facility. The aggregate market value of shares eligible for sale under the ATM Facility will be subject to the limitations of General Instruction I.B.6 of

Form S-3, to the extent required under such instruction. Following the capital raise through offerings described in Note 1. Nature of the Business, costs capitalized related to the ATM Facility of $0.4 million were written off during the quarter ended September 30, 2023, and reflected in general and administrative expenses in the accompanying financial statements.

Stock-Based Compensation

Teknova measures and recognizes compensation expense for all stock-based awards, including stock options, restricted stock units, and stock purchase rights granted under the Employee Stock Purchase Plan (ESPP) to employees, based on the estimated fair value of the awards on the date of grant. The fair value of each stock option granted and employee stock purchase rights are estimated using the Black-Scholes option-pricing model, which requires the Company to make a number of assumptions, including expected volatility, the expected risk-free interest rate, the expected term, and the expected dividend. The fair value of each restricted stock unit is based on the fair value of the Company’s common stock on the date of grant. Stock-based compensation expense is recognized over the requisite service period of the award, which generally represents the scheduled vesting period. Forfeitures are recognized as they occur.

Employee Benefit Plans

Teknova has a salary deferral 401(k) plan (the 401(k) Plan) covering substantially all employees. Contributions by the Company to the 401(k) Plan for the years ended December 31, 2023 and 2022 were $0.7 million and $0.6 million, respectively. Contributions payable as of December 31, 2023 and 2022, of $0.1 million and $0.1 million, respectively, are included within accrued liabilities in the accompanying financial statements.

Income Taxes

Teknova uses the asset and liability method in accounting for its deferred income taxes. Under this method, deferred income taxes are provided for differences between the carrying amounts of assets and liabilities for financial reporting and tax purposes, using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates on the date of enactment. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some or all of the deferred tax assets will not be realized.

Teknova accounts for unrecognized tax benefits based upon its assessment of whether tax benefits are more likely than not to be sustained upon examination by tax authorities. The Company reports a liability for unrecognized tax benefits taken, or expected to be taken, in a tax return and recognizes associated interest and penalties, if any, in income tax expense. Unrecognized tax benefits as of December 31, 2023 were $0.1 million and as of December 31 2022 were not significant.

Net Loss Per Share of Common Stock

Basic net income (loss) per share is computed using the two-class method. Diluted net income (loss) per share is computed using the more dilutive of (i) the treasury stock method or if-converted method, or (ii) the two-class method. The two-class method is an earnings allocation formula that determines net income per share for each class of common stock and participating security according to dividends declared and participation rights in undistributed earnings. The treasury stock method uses the number of new shares that may be created by unexercised in-the-money options, where the exercise price is less than the current share price. The if-converted method calculates the value of convertible securities as if they were converted into new shares. Per share amounts are computed by dividing net income (loss) by the weighted average shares outstanding during each period. The diluted net income (loss) per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period.

Recently Adopted Accounting Pronouncements

Effective January 1, 2023, the Company adopted Accounting Standard Update (ASU) No. 2016-13, Financial Instruments—Credit Losses (Topic 326), which introduced a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses and applied to the Company’s accounts receivable. The adoption of this standard did not have a significant impact on the Company’s financial statements.

Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Additionally, all disclosure requirements under the guidance are also required for public entities with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of this standard to determine its impact on the Company’s disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disclosure in the rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciliation items in some categories if the items meet a quantitative threshold. The guidance also requires disclosure of income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. The guidance is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of this standard to determine its impact on the Company’s disclosures.

Recent Securities and Exchange Commission (SEC) Final Rules Not Yet Adopted

In March 2024, the SEC adopted final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which requires registrants to provide certain climate-related information in their registration statements and annual reports. The rules require information about a registrant’s climate-related risks that have materially impacted, or are reasonably likely to have a material impact on its business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in the registrant’s audited financial statements. Disclosure requirements will begin phasing in for fiscal years beginning on or after January 1, 2025. The Company is currently evaluating the impact of these new final rules on its financial statements and disclosures.

Subsequent Events (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Millions			12 Months Ended
	Mar. 08, 2024	Jan. 11, 2024	Dec. 31, 2024	Dec. 31, 2022
Subsequent Event [Line Items]
Net revenue requirement for the financial covenant				$ 42.5
Amendment Number Five [Member]
Subsequent Event [Line Items]
Net revenue requirement for the financial covenant			$ 42.0
Forecast [Member] \| Amendment Number Five [Member]
Subsequent Event [Line Items]
Net revenue requirement for the financial covenant			$ 34.0
Subsequent Events [Member]
Subsequent Event [Line Items]
Severance and other related termination benefits		$ 1.2
Total annual cost saveing deposit		$ 6.4
Reduction in workforce position percentage		15.00%
Subsequent Event Description		On January 16, 2024, the board of directors of the Company approved a stock option repricing (the Option Repricing), which was effective on March 14, 2024 (the Repricing Date). The Option Repricing applies to outstanding options to purchase shares of common stock of the Company (the Common Stock) that, as of the Repricing Date, are held by employees and certain non-employee directors of the Company (the Outstanding Options), and were granted under the Company’s 2016 Plan, 2020 Plan, and 2021 Plan (collectively, the Plans). As of the Repricing Date, all Outstanding Options were repriced such that the exercise price per share for such Outstanding Options will be reduced to the Fair Market Value (as defined in the Plans) of the Common Stock on the Repricing Date (the New Price), effective as of the Price Reduction Date (as defined below), provided that the holder remains employed by the Company or continues to serve as a member of the board of directors through such date. The Price Reduction Date is the earliest to occur of (i) September 14, 2025, (ii) the date of the holder’s termination of employment or service with the Company due to (x) a termination by the Company without cause or (y) the holder’s resignation for good reason, or (iii) the date on which a change in control of the Company occurs. For the avoidance of doubt, other than in event of a change in control, the reduced exercise price only applies to exercises that occur on or after the Price Reduction Date and if a holder’s employment by or service to the Company has not ended (other than due to a termination by the Company without cause or a resignation for good reason) prior to the Price Reduction Date.
Subsequent Events [Member] \| Amendment Number Five [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Outstanding	125,000
Net Cash Requirement for Financial Convenant	$ 9.0
Achieving Revenue from the Preceding Month	$ 34.0
Stock with exercise price	$ 2.9934
Subsequent Events [Member] \| Forecast [Member]
Subsequent Event [Line Items]
Net Cash Requirement for Financial Convenant	$ 10.0
Achieving Revenue from the Preceding Month	45.0
Subsequent Events [Member] \| Amended Term Loan [Member]
Subsequent Event [Line Items]
Achieving Revenue from the Preceding Month	$ 38.0

Concentrations of Risk

12 Months Ended

Dec. 31, 2023

Fair Value, Concentration of Risk, Financial Assets, Balance Sheet Groupings [Abstract]

Concentrations of Risk

Note 4. Concentrations of Risk

Customers

Customers who accounted for 10% or more of the Company's revenues and outstanding balance of accounts receivable are presented as follows:


	For the Year Ended December 31,		As of December 31,
	2023	2022	2023	2022
Distributor customer A	18%	15%	16%	17%
Distributor customer B	*	*	*	15%

* Represents less than 10%.

The Company's customers that are distributors, as opposed to direct customers, represent highly diversified customer bases.

Suppliers

Suppliers who accounted for 10% or more of the Company's inventory purchases and outstanding balance of accounts payable are presented as follows:


	For the Year Ended December 31,		As of December 31,
	2023	2022	2023	2022
Distributor supplier A	40%	37%	18%	11%
Direct supplier A	*	14%	*	*
Direct supplier B	*	12%	*	*
Direct supplier C	10%	*	*	*

* Represents less than 10%.

The Company’s suppliers that are distributors, as opposed to direct suppliers, represent highly diversified supplier bases.

Contingencies - Additional Information (Details) $ in Millions	Dec. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Loss contingency, accrual	$ 0.3

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Major Classes of Property and Equipment (Details)	Dec. 31, 2023
Machinery and Equipment [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, useful life	15 years
Machinery and Equipment [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, useful life	5 years
Office Furniture and Equipment [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, useful life	7 years
Office Furniture and Equipment [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, useful life	3 years
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, useful life	5 years
Leasehold Improvements [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, useful life	15 years
Leasehold Improvements [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, useful life	3 years

Accrued Liabilities (Additional Information) (Details) - USD ($) $ in Thousands		12 Months Ended
	Jul. 25, 2023	Dec. 31, 2023	Dec. 31, 2022
Accrued Liabilities, Current [Abstract]
Insurance Premiums Paid	$ 1,200
Annual Interest Rate To Finance For Insurance Premiums	7.74%
Insurance Premiums Down Payment		$ 200
Insurance Premiums Frequency of Payments		600
Insurance Premiums And Accrued Interest		$ 409	$ 0

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 4,500	$ 2,000
Accumulated Capitalized Interest Costs	900	1,600
Long-lived assets impairment	$ 2,195	$ 4,188

Intangible Assets, Net - Schedule of Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 1,148
2025	1,148
2026	1,148
2027	45
Finite-Lived Intangible Assets, Net	$ 3,489

Subsequent Events

12 Months Ended

Dec. 31, 2023

Subsequent Events [Abstract]

Subsequent Events

Note 17. Subsequent Events

On January 11, 2024, the Company announced a reduction in its workforce that affected approximately 15% of its employees at that time. The Company estimates that it will incur approximately $1.2 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The Company expects the majority of the costs to be incurred and payments made during the first quarter of 2024. Total annual cost savings from the reduction in workforce are estimated at $6.4 million.

On January 16, 2024, the board of directors of the Company approved a stock option repricing (the Option Repricing), which was effective on March 14, 2024 (the Repricing Date). The Option Repricing applies to outstanding options to purchase shares of common stock of the Company (the Common Stock) that, as of the Repricing Date, are held by employees and certain non-employee directors of the Company (the Outstanding Options), and were granted under the Company’s 2016 Plan, 2020 Plan, and 2021 Plan (collectively, the Plans). As of the Repricing Date, all Outstanding Options were repriced such that the exercise price per share for such Outstanding Options will be reduced to the Fair Market Value (as defined in the Plans) of the Common Stock on the

Repricing Date (the New Price), effective as of the Price Reduction Date (as defined below), provided that the holder remains employed by the Company or continues to serve as a member of the board of directors through such date. The Price Reduction Date is the earliest to occur of (i) September 14, 2025, (ii) the date of the holder’s termination of employment or service with the Company due to (x) a termination by the Company without cause or (y) the holder’s resignation for good reason, or (iii) the date on which a change in control of the Company occurs. For the avoidance of doubt, other than in event of a change in control, the reduced exercise price only applies to exercises that occur on or after the Price Reduction Date and if a holder’s employment by or service to the Company has not ended (other than due to a termination by the Company without cause or a resignation for good reason) prior to the Price Reduction Date. If a holder exercises any of his or her Repriced Options (as defined below) prior to the Price Reduction Date, the original (unmodified, current) exercise price will continue to apply. In addition, in the event that an Outstanding Option has an exercise price that is less than the New Price, such Outstanding Option will not be repriced as part of the Option Repricing. The Outstanding Options that are repriced on the Repricing Date (the Repriced Options) will include the Outstanding Options held by our employees (including our executive officers) and certain non-employee directors. There will be no changes to the number of shares, the vesting schedule, or the expiration date of the Repriced Options. The Option Repricing will result in additional share-based compensation expense that will be recognized in the Company’s statements of operations in future periods; however, the amount of additional share-based compensation expense and the periods over which it will be recognized have not yet been determined.

On March 8, 2024, the Company entered into limited waivers and amendments (collectively Amendment No. 5, or, as amended, the Amended Credit Agreement) which includes a waiver from MidCap of the revenue covenant violations for each of the periods ending November 30, 2023 and January 31, 2024. Amendment No. 5 also reduced these requirements for future periods up to and including for the twelve months ending December 31, 2024, from $42 million to $34 million. Amendment No. 5 also removed those requirements for the periods ending January 31, 2025 through December 31, 2025, instead requiring that for each applicable twelve-month period ending after December 31, 2024, the Company’s minimum net revenue requirement will be determined by MidCap in its reasonable discretion in consultation with the Company’s senior management and based on financial statements and projections delivered to MidCap in accordance with the financial reporting requirements in the Amended Credit Agreement, so long as the minimum net revenue requirements for those periods shall not be less than the greater of (x) the applicable minimum net revenue requirement for the twelve-month period ending on the last day of the immediately preceding month and (y) $34.0 million. In addition, Amendment No. 5 also removed the advance rate for finished goods inventory in the determination of the borrowing base for the Revolving Loan and increased the minimum cash requirement from $9.0 million to $10.0 million. Finally, Amendment No. 5 conditions the next borrowing under the Revolving Loan on the Company achieving net revenue for the preceding twelve-month period of at least $38.0 million down from $45.0 million. The Amended Credit Agreement is unmodified in all other material respects.

On March 8, 2024, as a condition to the effectiveness of Amendment No. 5, the Company issued to MidCap Funding XXVII a warrant to purchase up to an aggregate of 125,000 shares (the Common Warrant) of Common Stock with an exercise price of $2.9934 per share, subject to adjustment as provided therein. The Common Warrant is exercisable immediately, and will expire on the earlier to occur of the (i) expiration of the Common Warrant pursuant to Section 1.6 thereof, or (ii) tenth (10th) anniversary of the Issue Date (as defined therein). The exercise price and number of shares of Common Stock issuable upon the exercise of the Common Warrant will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Common Warrant. MidCap may exercise the Common Warrant for cash or by means of a “cashless exercise.

Stock-Based Compensation - Schedule of Weighted-Average Assumptions used in Black-Scholes Option-Pricing Model (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Employee Stock Purchase Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Estimated dividend yield	0.00%	0.00%
Weighted-average expected stock price volatility	32.00%	43.00%
Weighted-average risk-free interest rate	5.37%	3.70%
Expected average term of options (in years)	6 months	6 months
Weighted-average fair value of common stock	$ 2.88	$ 7.2
Weighted-average fair value per option	$ 0.72	$ 1.96
Employee Stock Option Plans [Member]
Subsidiary, Sale of Stock [Line Items]
Estimated dividend yield	0.00%	0.00%
Weighted-average expected stock price volatility	35.10%	33.77%
Weighted-average risk-free interest rate	4.14%	2.79%
Expected average term of options (in years)	5 years 11 months 12 days	6 years 3 months
Weighted-average fair value of common stock	$ 5.03	$ 11.14
Weighted-average fair value per option	$ 2.11	$ 4.18

Nature of the Business

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations

Note 1. Nature of the Business

Alpha Teknova, Inc. (referred to herein as the Company or Teknova), produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Product offerings include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions, with catalog and custom, made-to-order products.

Teknova manufactures its products at its Hollister, California headquarters and stocks inventory of raw materials, components, and finished goods at that location. The Company ships products directly from its warehouse in Hollister, California.

Concurrent Registered Direct Offering and Private Placements

On September 15, 2023, the Company entered into a securities purchase agreement (the Registered Direct Purchase Agreement) in connection with a registered direct offering (the Registered Direct Offering) with certain accredited investors and qualified institutional buyers. On September 15, 2023, the Company also entered into a securities purchase agreement (the PIPE Purchase Agreement and, together with the Registered Direct Purchase Agreement, the Purchase Agreements) and a registration rights agreement (the Registration Rights Agreement) in connection with a concurrent private placement (the PIPE Private Placement) with certain accredited investors and qualified institutional buyers.

Pursuant to the Registered Direct Purchase Agreement, the Company sold 1,086,485 shares of the Company’s common stock, $0.00001 par value per share (the Common Stock) at an offering price of $1.85 per share. Pursuant to the PIPE Purchase Agreement, the Company sold 11,299,993 shares of Common Stock (the PIPE Shares), at the same offering price of $1.85 per share.

The Company’s controlling stockholder, Telegraph Hill Partners Management Company LLC, through its affiliates Telegraph Hill Partners IV, L.P. and THP IV Affiliates Fund, LLC, the Company’s President and Chief Executive Officer and a member of its board of directors, Stephen Gunstream, the Company’s Chief Financial Officer, Matthew Lowell, and the Company’s General Counsel and Chief Compliance Officer, Damon Terrill, and the Mackowski Family Trust, which is affiliated with J. Matthew Mackowski, a member of the Company’s board of directors, participated in the PIPE Private Placement and purchased an aggregate of 9,054,052 shares of common stock on the same terms as the other investors.

The Company received aggregate gross proceeds of $22.915 million from the Registered Direct Offering and PIPE Private Placement (collectively, the Offerings), before deducting offering expenses related to the Offerings. As of December 31, 2023, $0.4 million of costs directly related to these Offerings were included as a reduction to additional paid-in capital on the balance sheet.

The Offerings closed on September 19, 2023.

Property, Plant and Equipment Net - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 48,360	$ 27,863
Less—Accumulated depreciation	(7,528)	(4,520)
Property, plant and equipment, after depreciation	55,888	32,383
Construction in progress	2,004	23,714
Total property, plant and equipment, net	50,364	51,577
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	30,082	19,433
Office Furniture and Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	842	628
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	291	229
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 24,673	$ 12,093

Long-Term Debt - Summary of Scheduled Maturities of Term Loan (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Long-Term Debt, Unclassified [Abstract]
2024	$ 0
2025	3,539
2026	6,068
2027	2,528
Total	$ 12,135

Long-Term Debt - Additional Information (Details) - USD ($)					1 Months Ended	6 Months Ended		12 Months Ended
	Sep. 18, 2023	Mar. 28, 2023	Nov. 08, 2022	May 10, 2022	Nov. 30, 2022	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jul. 13, 2023	Jun. 30, 2023	Oct. 31, 2022	Oct. 05, 2022	Mar. 26, 2021
Debt Instrument [Line Items]
Maximum amount borrowed														$ 5,000,000
Line of Credit Facility, Current Borrowing Capacity															$ 5,000,000
Cash Received Under the Term Loan																$ 12,000,000
Maximum amount borrowed at the end of month														5,135,000
Unused Borrowing Capacity Amount							$ 10,000,000			$ 10,000,000			$ 10,000,000	$ 5,000,000	40,135,000
Contingent Revenue							15,000,000
Liquidity, line of credit										10,000,000
Line of Credit Facility, Description		removed the increase in the minimum cash covenant from $10.0 million to $15.0 million on the $10.0 million in borrowings in the first half of 2024, and added the $10.0 million minimum cash covenant requirement throughout the remaining term of the Credit Agreement		If any advance under the Term Loan was prepaid at any time, the prepayment fee was based on the amount being prepaid and an applicable percentage amount, such as 3%, 2%, or 1%, based on the date the prepayment was made after the closing date of the Term Loan.
Term Loan Exit Fee Rate				5.00%
Net revenue requirement for the financial covenant											$ 42,500,000
Loss on extinguishment of debt										(824,000)	0
Debt Instrument Covenant Description	No. 4 also removed those requirements for the periods ending January 31, 2026 through March 31, 2027, instead requiring that for each applicable twelve-month period ending after December 31, 2025, the Company’s minimum net revenue requirement was to be determined by MidCap in its reasonable discretion in consultation with the Company’s senior management and based on financial statements and projections delivered to MidCap in accordance with the financial reporting requirements in Amendment No. 4, so long as the minimum net revenue requirements for those periods shall not be less than the greater of (x) the applicable minimum net revenue requirement for the twelve-month period ending on the last day of the immediately preceding month and (y) $50.0
Payment of debt issuance costs										47,000	172,000
Long term debt							12,135,000			12,135,000	22,135,000
Long-term debt, net							$ 13,251,000			13,251,000	$ 21,976,000
Maximum [Member]
Debt Instrument [Line Items]
Term Loan Exit Fee Rate	9.00%		7.00%
Minimum [Member]
Debt Instrument [Line Items]
Term Loan Exit Fee Rate			5.00%
Forecast [Member]
Debt Instrument [Line Items]
Unused Borrowing Capacity Amount						$ 10,000,000
Contingent Revenue						19,000,000
Liquidity, line of credit						15,000,000
Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Maximum amount borrowed													$ 10,000,000
Increase Borrowing Capacity															15,000,000
Maturity date				May 01, 2027
Net revenue requirement for the financial covenant		$ 45,000,000								$ 42,000,000
Term Loan Exit Fee Percent	8.50%	7.00%								8.50%
Long-term line of credit			$ 10,000,000
Term Loan Prepayment	$ 10,000,000
Loss on extinguishment of debt										$ 800,000
Amended Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Maximum amount borrowed												$ 1,100,000
Cash Covenant Amount	9,000,000
Revenues										36,500,000
Amended Credit Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Maximum amount borrowed												$ 250,000
Cash Covenant Amount	10,000,000
Revenues	$ 45,000,000									$ 42,000,000
Amended Credit Agreement [Member] \| Forecast [Member]
Debt Instrument [Line Items]
Maximum amount borrowed						10,000,000
Amended Credit Agreement [Member] \| Forecast [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Revenues								$ 50,000,000	$ 42,000,000
Amended Credit Agreement [Member] \| Forecast [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Revenues								$ 58,800,000	$ 49,000,000
London Interbank Offered Rate [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				3.75%
LIBOR Floor [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				1.00%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Adjusted upward rate			0.10%
Term SOFR floor					1.00%
The Facility [Member]
Debt Instrument [Line Items]
Maximum amount borrowed															57,135,000
Revolver [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Term SOFR floor		4.50%
Revolver [Member] \| Amended Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Exit Fees Percentage of Term Loan		4.00%
Revolver [Member] \| Amended Credit Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Exit Fees Percentage of Term Loan		3.75%
Revolver [Member] \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Applicable Margin			3.75%
Clinical Solution [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Maximum amount borrowed						10,000,000
Cash Covenant Amount						$ 10,000,000
Clinical Solution [Member] \| Amended Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Cash Covenant Amount		$ 15,000,000
Clinical Solution [Member] \| Amended Credit Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Cash Covenant Amount		$ 10,000,000
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Maximum amount borrowed															$ 52,135,000
Term Loan [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Term SOFR floor		1.00%
Term Loan [Member] \| Amended Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Applicable Margin		7.00%
Term Loan [Member] \| Amended Credit Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Applicable Margin		6.45%
Term Loan [Member] \| London Interbank Offered Rate [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				6.45%
Term Loan [Member] \| LIBOR Floor [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				1.00%
Term Loan [Member] \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Applicable Margin			6.45%

Inventories, Net

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Inventories, Net

Note 5. Inventories, Net

Inventories consist of the following (in thousands):


	As of December 31,
	2023		2022
Finished goods, net	$	8,573	$	8,368
Work in process		47		186
Raw materials, net		2,974		3,693
Total inventories, net	$	11,594	$	12,247

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Summary of Stock Options Activity

The following table summarizes the stock option activity for the year ended December 31, 2023 (in thousands, except share and per share data):


	Number of Shares			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2023		3,846,532		$	7.02		8.31	$	9,083
Granted		616,235		$	5.03		—		—
Exercised		(51,774	)	$	1.47		—		—
Forfeited		(280,793	)	$	10.17		—		—
Expired		(88,393	)	$	14.34		—		—
Outstanding at December 31, 2023		4,041,807		$	6.41		7.53	$	5,159
Exercisable at December 31, 2023		2,201,714		$	5.63		7.21	$	3,692
Vested and expected to vest at December 31, 2023		3,757,125		$	6.86		7.72	$	4,226

Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]

The following table summarizes the restricted stock unit activity for the year ended December 31, 2023 (in thousands, except share and per share data):


	Number of Shares			Weighted Average Grant Date Fair Value per Share		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2023		28,071		$	7.43		0.42	$	158
Granted		174,595		$	4.93		—		—
Vested		(28,071	)	$	7.43		—		—
Forfeited		(18,815	)	$	3.93		—		—
Outstanding at December 31, 2023		155,780		$	5.05		1.36	$	581
Vested and expected to vest at December 31, 2023		155,780		$	5.05		1.36	$	581

Schedule of Stock-Based Compensation Expense

Stock-based compensation expense included in the accompanying financial statements was as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
Cost of sales	$	142	$	147
Research and development		162		187
Sales and marketing		660		504
General and administrative		3,173		2,873
Total stock-based compensation expense	$	4,137	$	3,711

Schedule of Weighted-Average Assumptions used in Black-Scholes Option-Pricing Model

The weighted average assumptions used in the Black-Scholes option-pricing model are as follows:


	For the Year Ended December 31,
	Employee Stock Option Plans						Employee Stock Purchase Plan
	2023			2022			2023			2022
Estimated dividend yield		-	%		-	%		-	%		-	%
Weighted-average expected stock price volatility		35.10	%		33.77	%		32.00	%		43.00	%
Weighted-average risk-free interest rate		4.14	%		2.79	%		5.37	%		3.70	%
Expected average term of options (in years)		5.95			6.25			0.50			0.50
Weighted-average fair value of common stock	$	5.03		$	11.14		$	2.88		$	7.20
Weighted-average fair value per option	$	2.11		$	4.18		$	0.72		$	1.96

Schedule of Weighted-Average Assumptions used in Black-Scholes Option-Pricing Model

The weighted average assumptions used in the Black-Scholes option-pricing model are as follows:


	For the Year Ended December 31,
	Employee Stock Option Plans						Employee Stock Purchase Plan
	2023			2022			2023			2022
Estimated dividend yield		-	%		-	%		-	%		-	%
Weighted-average expected stock price volatility		35.10	%		33.77	%		32.00	%		43.00	%
Weighted-average risk-free interest rate		4.14	%		2.79	%		5.37	%		3.70	%
Expected average term of options (in years)		5.95			6.25			0.50			0.50
Weighted-average fair value of common stock	$	5.03		$	11.14		$	2.88		$	7.20
Weighted-average fair value per option	$	2.11		$	4.18		$	0.72		$	1.96

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets with Definite and Indefinite Lives

The following is a summary of intangible assets with definite and indefinite lives (in thousands):


	Balance at December 31, 2023						Balance at December 31, 2022
	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
Definite Lived:
Customer relationships	$	9,180	$	5,691	$	3,489	$	9,180	$	4,543	$	4,637
Indefinite Lived:
Tradename(1)		10,750		—		10,750		12,919		—		12,919
Total intangible assets	$	19,930	$	5,691	$	14,239	$	22,099	$	4,543	$	17,556

(1) During the year ended December 31, 2023, a charge of $2.2 million was recorded on our indefinite lived tradename asset as such to reflect the impairment of the value ascribed to the indefinite lived tradename asset.

Schedule of Future Amortization Expense

The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands):


	Amount
2024	$	1,148
2025		1,148
2026		1,148
2027		45
Estimated future amortization expense of definite-lived intangible assets	$	3,489

Leases - Schedule of maturities of operating lease liabilities (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Lessee Disclosure [Abstract]
2024	$ 2,601
2025	2,354
2026	2,413
2027	2,416
2028	2,265
Thereafter	9,652
Total lease payments	21,701
Less: imputed interest	(4,494)
Present value of lease liabilities	$ 17,207

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Summary of Components of Carrying Value of Long-Term Debt

Long-term debt, net consists of the following (in thousands):


	As of December 31,
	2023			2022
Long-term debt	$	12,135		$	22,135
Cumulative accretion of exit fee		1,261			161
Unamortized debt discount and debt issuance costs		(145	)		(320	)
Long-term debt, net	$	13,251		$	21,976

Schedule of Maturities of Term Loan

At December 31, 2023, the scheduled maturities of the Company's debt obligations were as follows (in thousands):


	Amount
2024	$	—
2025		3,539
2026		6,068
2027		2,528
Total	$	12,135

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

+ Details

Stock-Based Compensation

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

Note 11. Stock-Based Compensation

Equity Incentive Plans

Teknova maintains stock incentive plans for the benefit of certain of Teknova's officers, directors, consultants and employees. The Company granted time-based and performance-based options to purchase common shares under both its 2016 Stock Plan, as amended (2016 Plan) and 2020 Equity Incentive Plan, as amended (2020 Plan). At the time the 2020 Plan became effective, no additional stock awards were granted or are able to be granted in the future under the 2016 Plan. In June 2021, the Company’s board of directors and the Company’s stockholders approved the 2021 Equity Incentive Plan (2021 Plan), which became effective in connection with the IPO. From and after the date on which the 2021 Plan became effective, no further grants were made or will be made under the 2020 Plan. At December 31, 2023, 3,193,511 shares of the Company's common stock remain available for future grants under the 2021 Plan.

The types of equity-based awards that may be granted under the 2021 Plan include: incentive stock options or nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other stock-based awards. The equity-based awards for employees will vest over a four-year period, pursuant to two different vesting schedules. For initial equity-based awards granted to employees, the first vest is generally a one-year cliff vest, followed by monthly vesting for the final three years. Thereafter, annual equity-based awards granted to employees typically vest monthly over the four-year vest term. The initial equity-based awards granted to the Company’s non-employee, independent directors upon appointment to the board of directors will vest over a three-year period, with the first vest being a one-year cliff, followed by monthly vesting over the remaining two years. Thereafter, annual equity-based awards granted to the Company’s non-employee, independent directors will cliff vest after one year from the date of grant.

Generally, the number of shares of the Company’s common stock that will be reserved for issuance under the 2021 Plan will automatically increase on January 1 of each year for a period of ten years, beginning on January 1, 2022, and continuing through January 1, 2031, in an amount equal to 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding year; provided, however, that the Company’s board of directors may act prior to January 1 of a given year to provide that the increase for such year will be a lesser number of shares of common stock. Effective January 1, 2024, an additional 1,631,753 new shares became available for issuance under the 2021 Plan.

Stock Options

The following table summarizes the stock option activity for the year ended December 31, 2023 (in thousands, except share and per share data):


	Number of Shares			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2023		3,846,532		$	7.02		8.31	$	9,083
Granted		616,235		$	5.03		—		—
Exercised		(51,774	)	$	1.47		—		—
Forfeited		(280,793	)	$	10.17		—		—
Expired		(88,393	)	$	14.34		—		—
Outstanding at December 31, 2023		4,041,807		$	6.41		7.53	$	5,159
Exercisable at December 31, 2023		2,201,714		$	5.63		7.21	$	3,692
Vested and expected to vest at December 31, 2023		3,757,125		$	6.86		7.72	$	4,226

The total intrinsic value of options exercised during the year ended December 31, 2023 and 2022 was $0.1 million and $0.9 million, respectively. The aggregate grant-date fair value of options vested during the year ended December 31, 2023 and 2022, was $4.7 million and $3.9 million, respectively.

Restricted Stock Units

The following table summarizes the restricted stock unit activity for the year ended December 31, 2023 (in thousands, except share and per share data):


	Number of Shares			Weighted Average Grant Date Fair Value per Share		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2023		28,071		$	7.43		0.42	$	158
Granted		174,595		$	4.93		—		—
Vested		(28,071	)	$	7.43		—		—
Forfeited		(18,815	)	$	3.93		—		—
Outstanding at December 31, 2023		155,780		$	5.05		1.36	$	581
Vested and expected to vest at December 31, 2023		155,780		$	5.05		1.36	$	581

The aggregate grant-date fair value of restricted stock units vested during the year ended December 31, 2023 and 2022, was $0.2 million and zero, respectively.

Employee Stock Purchase Plan

In June 2021, the Company’s board of directors and the Company’s stockholders, respectively, approved the Company’s 2021 Employee Stock Purchase Plan (the ESPP), which became effective in connection with the IPO. At December 31, 2023, 656,134 shares of the Company’s common stock remain available for issuance under the ESPP. The number of shares of the Company’s common stock that will be reserved for issuance will automatically increase on January 1 of each year for a period of ten years, beginning on January 1, 2022, and continuing through January 1, 2031, by the lesser of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding year; and (ii) 319,911 shares (subject to adjustments for stock splits, dividends, combinations of shares, exchanges of shares, and other “Capitalization Adjustments”, as defined in the ESPP), except before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). Effective January 1, 2024, an additional 319,911 new shares became available for issuance under the ESPP.

Generally, all regular employees, including executive officers, employed by the Company will be eligible to participate in the ESPP and to contribute, normally through payroll deductions, up to 15% of their earnings (as defined in the ESPP) for the purchase of the Company’s common stock under the ESPP. Unless otherwise determined by the Company’s board of directors, shares of the Company’s common stock will be purchased for the accounts of employees participating in the Company’s ESPP at a price per share equal to the lesser of (i) 85% of the fair market value of a share of the Company’s common stock on the first day of an offering; or (ii) 85% of the fair market value of a share of the Company’s common stock on the date of purchase. Offering periods are generally six months long. Beginning on May 15, 2023, offering periods begin on June 1 and December 1 of each year. Prior to this time, offering periods began on May 15 and November 15 of each year.

Valuation of Employee Share-Based Awards

Teknova uses the Black-Scholes option-pricing model to determine the fair value of stock options. The valuation model for stock compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term, expected volatility and fair value of the Company’s common stock, and an assumed risk-free interest rate. The assumptions used in the Black-Scholes option-pricing model were as follows:

Volatility. Since the Company has limited historical data on volatility of its stock, expected volatility is based on the volatility of the stock of similar publicly traded entities. In evaluating similarity, the Company considers factors such as industry, stage of life cycle, size, and financial leverage.

Fair value of underlying common stock. The fair value of the Company’s common stock is determined by the closing price of its common stock as reported on the Nasdaq Global Market on the date of grant.

Risk-free interest rate. The risk-free rate that the Company uses is based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options.

Expected term. As the Company does not have sufficient historical exercise activity to estimate expected life, the expected life of options granted is determined using the simplified method. The simplified method is based on the vesting period and the contractual term for each grant or for each vesting tranche for awards with graded vesting. The midpoint of the vesting date and the maximum contractual expiration date are used to determine the expected term under this method.

Dividend yield. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero. In addition, the terms of the Amended Credit Agreement prohibit us from paying dividends, other than dividends payable in the Company’s common stock, without the prior consent of the lender.

The weighted average assumptions used in the Black-Scholes option-pricing model are as follows:


	For the Year Ended December 31,
	Employee Stock Option Plans						Employee Stock Purchase Plan
	2023			2022			2023			2022
Estimated dividend yield		-	%		-	%		-	%		-	%
Weighted-average expected stock price volatility		35.10	%		33.77	%		32.00	%		43.00	%
Weighted-average risk-free interest rate		4.14	%		2.79	%		5.37	%		3.70	%
Expected average term of options (in years)		5.95			6.25			0.50			0.50
Weighted-average fair value of common stock	$	5.03		$	11.14		$	2.88		$	7.20
Weighted-average fair value per option	$	2.11		$	4.18		$	0.72		$	1.96

Summary of Stock-Based Compensation Expense

Stock-based compensation expense included in the accompanying financial statements was as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
Cost of sales	$	142	$	147
Research and development		162		187
Sales and marketing		660		504
General and administrative		3,173		2,873
Total stock-based compensation expense	$	4,137	$	3,711

Stock-based compensation expense related to stock options was $3.7 million and $3.5 million for the years ended December 31, 2023 and 2022, respectively. Unrecognized compensation expense related to stock options was $6.5 million at December 31, 2023, which is expected to be recognized as expense over the weighted-average period of 2.82 years.

Stock-based compensation expense related to restricted stock units was $0.3 million and $0.1 million for the years ended December 31, 2023 and 2022, respectively. Unrecognized compensation expense related to restricted stock units was $0.6 million at December 31, 2023, which is expected to be recognized as expense over the weighted-average period of 2.50 years.

During the year ended December 31, 2021, the Company’s board of directors approved an amendment to the outstanding performance-based option to acquire 231,719 shares of the Company’s common stock previously granted under 2020 Plan, to eliminate the performance-based vesting and provide that such option will vest in 48 equal monthly installments. The stock option modification was measured as the excess of the fair value of the modified option over the fair value of the original option immediately before the modification. The incremental stock-based compensation expense for such stock option modification is approximately $3.5 million, of which $0.9 million of incremental stock-based compensation expense was recognized during each of the years ended December 31, 2023 and 2022, in general and administrative expenses in the accompanying financial statements. Additionally, in January 2019, the Company granted 284,682 performance-based options that vest upon a change of control. As of December 31, 2023, these options were not considered probable of vesting. The Company had unrecognized compensation expense of approximately $0.5 million at December 31, 2023, relating to these options.

Total stock-based compensation expense related to the ESPP was $0.1 million and not significant for the years ended December 31, 2023 and 2022, respectively. Total compensation cost related to the ESPP not yet recognized is also not significant. As of December 31, 2023, an insignificant amount has been withheld on behalf of employees for a future purchase under the ESPP. The Company issued 148,102 and 48,506 shares of common stock under the ESPP during the years ended December 31, 2023 and 2022, respectively.

Stock-Based Compensation - Summary of Stock Options Activity (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding, Beginning balance	3,846,532
Number of Options, Granted	616,235
Number of Options, Exercised	(51,774)
Number of Options, Forfeited	(280,793)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period	(88,393)
Number of Options, Outstanding, Ending balance	4,041,807	3,846,532
Number of Options, Exercisable, Ending balance	2,201,714
Number of Options, Vested and expected to vest	3,757,125
Weighted Average Exercise Price per Share, Options outstanding, Beginning balance	$ 7.02
Weighted Average Exercise Price per Share, Granted	5.03
Weighted Average Exercise Price per Share, Exercised	1.47
Weighted Average Exercise Price per Share, Forfeited	(10.17)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	14.34
Weighted Average Exercise Price per Share, Options outstanding, Ending balance	6.41	$ 7.02
Weighted Average Exercise Price per Share, Exercisable, Ending balance	5.63
Weighted Average Exercise Price per Share, Vested and expected to vest	$ 6.86
Weighted Average Remaining Contractual Term (in years), Options outstanding	7 years 6 months 10 days	8 years 3 months 21 days
Weighted Average Remaining Contractual Term (in years), Exercisable	7 years 2 months 15 days
Weighted Average Remaining Contractual Term (in years), Vested and expected to vest	7 years 8 months 19 days
Aggregate Intrinsic Value, Options outstanding	$ 5,159	$ 9,083
Aggregate Intrinsic Value, Exercisable	3,692
Aggregate Intrinsic Value, Vested and expected to vest	$ 4,226

Statements of Stockholders Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]
Beginning Balance at Dec. 31, 2021	$ 143,203		$ 150,741	$ (7,538)
Beginning Balance (in shares) at Dec. 31, 2021		28,012,017
Stock-based compensation	3,711		3,711
Issuance of common stock upon exercise of stock options In Shares		118,900
Issuance of common stock upon exercise of stock options	145		145
Issuance of common stock under employee stock purchase plan (In Share)		48,506
Issuance of common stock under employee stock purchase plan	294		294
Net income (loss)	(47,468)			(47,468)
Ending Balance at Dec. 31, 2022	$ 99,885		154,891	(55,006)
Ending Balance (in shares) at Dec. 31, 2022	28,179,423	28,179,423
Stock-based compensation	$ 4,137		4,137
Issuance of common stock upon exercise of stock options In Shares		51,774
Issuance of common stock upon exercise of stock options	76		76
Issuance of common stock under employee stock purchase plan (In Share)		148,102
Issuance of common stock under employee stock purchase plan	252		252
Vesting of restricted stock units, Shares		28,071
Equity financing, net of issuance costs (in shares)		12,386,478
Equity financing, net of issuance costs	22,466		22,466
Net income (loss)	(36,780)			(36,780)
Ending Balance at Dec. 31, 2023	$ 90,036		$ 181,822	$ (91,786)
Ending Balance (in shares) at Dec. 31, 2023	40,793,848	40,793,848

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Jan. 01, 2022	Jan. 31, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2024
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense			$ 4,137	$ 3,711
General and Administrative Expense			$ 25,450	$ 28,298
Common stock, shares issued			40,793,848	28,179,423
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense			$ 600
Stock-based compensation expense related to employee stock option			$ 300	$ 100
Weighted-average recognition period			2 years 6 months
Grant date fair value of shares vested			$ 200	0
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense			6,500
Stock-based compensation expense related to employee stock option			$ 3,700	3,500
Weighted-average recognition period			2 years 9 months 25 days
Intrinsic value of options			$ 100	900
Grant date fair value of shares vested			$ 4,700	3,900
Number of Options, Exercised			51,774
Number of Options, Granted			616,235
Performance Based Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense			$ 500
Total stock-based compensation expense			3,500	3,500
Shares outstanding, Acquired from Performance plan Issuance					231,719
General and Administrative Expense			$ 900	$ 900
Number of Options, Granted		284,682
2021 Equity Incentive Plans [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of total common stock outstanding	4.00%
Additional shares to be issued under share-based payment arrangement						1,631,753
Vesting period			3 years
Increase in common stock reserved for future issuance, term period	10 years
Common stock reserved for future issuance			3,193,511
2021 Equity Incentive Plans [Member] \| Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			4 years
Vesting, description			The equity-based awards for employees will vest over a four-year period, pursuant to two different vesting schedules. For initial equity-based awards granted to employees, the first vest is generally a one-year cliff vest, followed by monthly vesting for the final three years. Thereafter, annual equity-based awards granted to employees typically vest monthly over the four-year vest term
2021 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share available for future grants	319,911
Additional shares to be issued under share-based payment arrangement						319,911
Increase in common stock reserved for future issuance, term period	10 years
Percentage of additional shares added on outstanding shares	1.00%
Stock-based compensation expense related to employee stock option			$ 100
Common stock reserved for future issuance			656,134
Maximum employee subscription rate			15.00%
Discount from market price, offering date			85.00%
Discount from market price, purchase date			85.00%
Issuance of common stock under employee stock purchase plan (In Share)			148,102	48,506
Employee Stock Purchase Plan, Offering Period			Offering periods are generally six months long. Beginning on May 15, 2023, offering periods begin on June 1 and December 1 of each year. Prior to this time, offering periods began on May 15 and November 15 of each year.

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Revenue	$ 36,684	$ 41,420
United States [Member]
Disaggregation Of Revenue [Line Items]
Revenue	35,000	40,103
Non-US [Member]
Disaggregation Of Revenue [Line Items]
Revenue	1,684	1,317
Lab Essentials [Member]
Disaggregation Of Revenue [Line Items]
Revenue	28,800	31,772
Clinical Solutions [Member]
Disaggregation Of Revenue [Line Items]
Revenue	6,738	8,445
Other Product [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,146	$ 1,203

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Leases (Tables)

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Schedule Of Maturities Of Operating Lease Liabilities

Maturities of operating lease liabilities at December 31, 2023, is as follows (in thousands):


	Amount
2024	$	2,601
2025		2,354
2026		2,413
2027		2,416
2028		2,265
Thereafter		9,652
Total lease payments		21,701
Less: imputed interest		(4,494	)
Present value of lease liabilities	$	17,207

Inventories, Net (Tables)

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories consist of the following (in thousands):


	As of December 31,
	2023		2022
Finished goods, net	$	8,573	$	8,368
Work in process		47		186
Raw materials, net		2,974		3,693
Total inventories, net	$	11,594	$	12,247

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Accounting, Presentation, and Use of Estimates

Going Concern

Segment Reporting

Concentrations of Credit Risk

Cash and Cash Equivalents

Fair Value of Financial Instruments

Accounts Receivable

Inventories

Capitalized Software Implementation Costs

Property, Plant, and Equipment

The estimated useful lives of the major classes of property and equipment are as follows:


		Estimated Useful Lives
Machinery and equipment		5 – 15 years
Office furniture and equipment		3 – 7 years
Vehicles		5 years
Leasehold improvements		3 – 15 years

Impairment of Long-Lived Assets

Intangible Assets

Teknova’s intangible assets consist of the Teknova trade name and the Company’s customer relationships.

whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the related assets’ or asset group’s carrying value.

Leases

Debt Issuance Costs

Revenue Recognition

We account for revenue in accordance with ASC 606, Revenue From Contracts With Customers. Teknova recognizes revenue for sales of goods through the following steps:

▪

Identification of the contract, or contracts, with a customer, typically a purchase order

▪

Identification of the performance obligations in the contract

▪

Determination of the transaction price

▪

Allocation of the transaction price to the performance obligations in the contract

▪

Recognition of revenue when, or as, the company satisfies a performance obligation

is recognized. Shipping and handling costs for the years ended December 31, 2023 and 2022 were $1.2 million and $1.4 million, respectively.

Costs incurred to obtain contracts with customers are expensed immediately, because the amortization period for such costs is one year or less.

Cost of Sales

Research and Development Expenses

Sales and Marketing Expenses

General and Administrative Expenses

Reduction in Workforce

At-the-Market Facility

Stock-Based Compensation

Employee Benefit Plans

Income Taxes

Net Loss Per Share of Common Stock

Recently Adopted Accounting Pronouncements

Accounting Pronouncements Not Yet Adopted

Recent Securities and Exchange Commission (SEC) Final Rules Not Yet Adopted

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 4,137	$ 3,711
Cost of Sales [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	142	147
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	162	187
Selling and Marketing Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	660	504
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,173	$ 2,873

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Property, Plant and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant, and equipment consist of the following (in thousands):


	As of December 31,
	2023			2022
Machinery and equipment	$	30,082		$	19,433
Office furniture and equipment		842			628
Vehicles		291			229
Leasehold improvements		24,673			12,093
		55,888			32,383
Less—Accumulated depreciation		(7,528	)		(4,520	)
		48,360			27,863
Construction in progress		2,004			23,714
Total property, plant, and equipment, net	$	50,364		$	51,577

Other Financial Information

12 Months Ended

Dec. 31, 2023

Other Financial Information Abstract

Other Financial Information

Note 15. Other Financial Information

The change in the allowance for doubtful accounts is as follows:


	For the Year Ended December 31,
	2023			2022
Beginning balance	$	22		$	23
Provisions (benefits)		21			25
Recoveries (write-offs), net		(23	)		(26	)
Ending balance	$	20		$	22

The change in the inventory reserve is as follows:


	For the Year Ended December 31,
	2023			2022
Beginning balance	$	1,046		$	470
Provisions (benefits)		323			697
Write-offs and other		(678	)		(121	)
Ending balance	$	691		$	1,046

The change in the income tax valuation allowance is as follows:


	For the Year Ended December 31,
	2023		2022
Beginning balance	$	7,170	$	477
Additions charged to expense		9,668		6,693
Reductions charged to other accounts		—		—
Ending balance	$	16,838	$	7,170

The change in unrecognized tax benefits are as follows:


	For the Year Ended December 31,
	2023		2022
Beginning balance	$	42	$	—
Tax positions related to the current year:
Additions		86		42
Reductions		—		—
Tax positions related to the prior year:
Additions		8		—
Reductions		—		—
Ending balance	$	136	$	42

Related Parties

12 Months Ended

Dec. 31, 2023

Related Parties

Note 14. Related Parties

The Company has identified Meeches LLC (Meeches) as a related party through common control. Meeches is controlled by Ted Davis and Irene Davis, founders and current directors, and greater than five percent stockholders of the Company. Prior to May 16, 2023, the Company leased certain real property in Mansfield, Massachusetts, from Meeches. As of December 31, 2023 and 2022 the Company did not have any outstanding balances owed to Meeches. For the years ended December 31, 2023 and 2022, the Company paid Meeches lease payments of $0.1 million and $0.3 million, respectively.

On April 11, 2023, the Company and Meeches entered into an agreement to terminate the Mansfield lease, which termination occurred on May 16, 2023. Shortly thereafter, Meeches sold the property to a third party. As part of the consideration for the early termination of the Mansfield lease, the Company entered into an escrow agreement with the new owner on May 17, 2023, and placed in escrow an amount equal to five months of base rent plus related expenses assumed by Teknova under the Mansfield lease. Escrow funds were released to the new owner on a pro-rata monthly basis. No amounts remain in escrow at December 31, 2023.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

Other Financial Information - Change in the inventory reserve (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Change in Accounting Estimate [Line Items]
Beginning balance	$ 22	$ 23
Provisions (benefits)	21	25
Recoveries (write-offs), net	(23)	(26)
Ending balance	20	22
Inventory reserve [Member]
Change in Accounting Estimate [Line Items]
Beginning balance	1,046	470
Provisions (benefits)	323	697
Recoveries (write-offs), net	(678)	(121)
Ending balance	$ 691	$ 1,046

Related Parties - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Meeches LLC [Member]
Related Party Transaction [Line Items]
Payment for Rent Expense	$ 0.1	$ 0.3

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net (Loss) Income Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Net loss	$ (36,780)	$ (47,468)
Earnings Per Share, Diluted, Other Disclosure [Abstract]
Basic weighted-average common stock outstanding	31,819,776	28,083,563
Dilutive weighted-average common stock	31,819,776	28,083,563
Earnings Per Share, Basic [Abstract]
Basic	$ (1.16)	$ (1.69)
Diluted	$ (1.16)	$ (1.69)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2023	Mar. 22, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Entity Registrant Name	ALPHA TEKNOVA, INC.
Entity Central Index Key	0001850902
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction Flag	false
Entity Shell Company	false
Document Fiscal Period Focus	FY
Trading Symbol	TKNO
Title of 12(b) Security	Common Stock, par value $0.00001 per share
Security Exchange Name	NASDAQ
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-40538
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3368109
Entity Address, Address Line One	2451 Bert Dr.
Entity Address, City or Town	Hollister
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95023
City Area Code	831
Local Phone Number	637-1100
Entity Public Float			$ 18,703,398
Entity Common Stock, Shares Outstanding		40,823,387
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	San Jose, CA
Documents Incorporated by Reference	Portions of the Registrant’s Proxy Statement relating to the 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement, or an amendment to this Annual Report on Form 10-K, will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2023.

Summary of Significant Accounting Policies - Additional Information (Details)			12 Months Ended
	Mar. 30, 2023 USD ($)	Feb. 01, 2023 USD ($) Positions	Dec. 31, 2023 USD ($) Segment	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Product Information [Line Items]
Operating segment \| Segment			1
Reportable segment \| Segment			1
Net losses			$ 36,780,000	$ 47,468,000
Accumulated Deficit			91,786,000	55,006,000
Total gross value of borrowings outstanding			12,135,000	22,135,000
Working Capital			36,800,000
Cash and cash equivalents			28,484,000	42,236,000
Cash, FDIC insured amount			250,000
Capitalized Software Implementation Costs			1,800,000	2,200,000
Amortization expense related to capitalized implementation costs			400,000	100,000
Unrecognized Tax Benefits			136,000	42,000	$ 0
Operating lease right-of-use assets			16,472,000	19,736,000
Operating Lease, Liability			17,207,000
Selling and Marketing Expense [Member]
Product Information [Line Items]
Marketing and Advertising Expense			100,000	0
General and Administrative Expense [Member]
Product Information [Line Items]
Shipping and handling charges			1,200,000	1,400,000
401K Plan [Member]
Product Information [Line Items]
Defined contribution plan, employer contribution amount			700,000	600,000
Contributions payable			100,000	$ 100,000
ATM Facility
Product Information [Line Items]
Maximum Value Of Stock To Be Issued Under ATM Facility	$ 50,000,000
Percentage of commission to be paid on gross sales proceeds of ATM facility	3.00%
Cost Capitalization Related to ATM Facility			$ 400,000
Reduction in Force [Member ]
Product Information [Line Items]
Severance And Other Related Termination Benefits		$ 700,000
Reduction in workforce of positions \| Positions		40

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 28,484	$ 42,236
Accounts receivable, net of allowance for doubtful accounts of $20 thousand and $22 thousand	3,948	4,261
Inventories, net	11,594	12,247
Income taxes receivable	0	22
Prepaid expenses and other current assets	1,634	2,374
Total current assets	45,660	61,140
Property, plant and equipment, net	50,364	51,577
Operating lease right-of-use assets	16,472	19,736
Intangible assets, net	14,239	17,556
Other non-current assets	1,852	2,252
Total assets	128,587	152,261
Current liabilities:
Accounts payable	1,493	2,449
Accrued liabilities	5,579	6,203
Current portion of operating lease liabilities	1,803	2,223
Total current liabilities	8,875	10,875
Deferred tax liabilities	919	1,223
Other accrued liabilities	102	191
Long-term debt	13,251	21,976
Long-term operating lease liabilities	15,404	18,111
Total liabilities	38,551	52,376
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively, zero shares issued and outstanding at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.00001 par value, 490,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively, 40,727,780 and 28,179,423 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Additional paid-in capital	181,822	154,891
Accumulated deficit	(91,786)	(55,006)
Total stockholders’ equity	90,036	99,885
Total liabilities and stockholders equity	$ 128,587	$ 152,261

Concentrations of Risk - Summary of inventory purchases and outstanding balance of accounts payable (Details) - Customers Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Inventory Purchases [Member] \| Distributor customer A [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration Risk, Percentage	40.00%	37.00%
Inventory Purchases [Member] \| Direct supplier A [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration Risk, Percentage		14.00%
Inventory Purchases [Member] \| Direct supplier B [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration Risk, Percentage		12.00%
Inventory Purchases [Member] \| Direct supplier C [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration Risk, Percentage	10.00%
Accounts Payable [Member] \| Distributor customer A [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration Risk Percentage	18.00%	11.00%

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Allowance for doubtful accounts	$ 20	$ 22
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	490,000,000	490,000,000
Common stock, shares issued	40,793,848	28,179,423
Common stock, shares outstanding	40,793,848	28,179,423

Other Financial Information - Change in the income tax valuation allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Regulatory Asset [Line Items]
Beginning balance	$ 22	$ 23
Additions charged to expense	21	25
Reductions charged to other accounts	(23)	(26)
Ending balance	20	22
Income tax valuation allowance [Member]
Regulatory Asset [Line Items]
Beginning balance	7,170	477
Additions charged to expense	9,668	6,693
Reductions charged to other accounts	0	0
Ending balance	$ 16,838	$ 7,170

Intangible Assets, Net - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Indefinite And Definite Lived Intangible Assets [Line Items]
Weighted Average Cost Of Capital	18.00%
Implied control premium	25.00%
Goodwill impairment charge	$ 0	$ 16,613,000
Amortization of Intangible Assets, Total	$ 1,148,000	1,148,000
Acquired finite-lived intangible assets, weighted average useful life	3 years
Tradename impairment	$ 2,169,000	0
Impairment of intangible assets	0	$ 0
Carrying value of indefinite lived	$ 10,800,000

Other Financial Information - Change in the allowance for doubtful accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable, Unclassified [Abstract]
Beginning balance	$ 22	$ 23
Provisions (benefits)	21	25
Recoveries (write-offs), net	(23)	(26)
Ending balance	$ 20	$ 22

Property, Plant and Equipment, Net

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, Net

Note 6. Property, Plant, and Equipment, Net

Property, plant, and equipment consist of the following (in thousands):


	As of December 31,
	2023			2022
Machinery and equipment	$	30,082		$	19,433
Office furniture and equipment		842			628
Vehicles		291			229
Leasehold improvements		24,673			12,093
		55,888			32,383
Less—Accumulated depreciation		(7,528	)		(4,520	)
		48,360			27,863
Construction in progress		2,004			23,714
Total property, plant, and equipment, net	$	50,364		$	51,577

Depreciation expense related to property, plant, and equipment recorded for the years ended December 31, 2023 and 2022 was $4.5 million and $2.0 million, respectively.

Teknova capitalizes interest on funds borrowed to finance certain of its capital expenditures. Capitalized interest is recorded as part of an asset’s cost and depreciated over the asset’s useful life. Capitalized interest costs were $0.9 million and $1.6 million for the years ended December 31, 2023 and 2022, respectively.

In June 2023, the Company identified circumstances that indicated certain of its machinery and equipment may not be fully recoverable. Specifically, these circumstances included changes in the market price of the asset group, continued losses, and an expectation that, more likely than not, the long-lived assets in question would be sold or otherwise disposed of significantly before the end of their previously estimated useful life. The Company reviewed the recoverability of the carrying value of these assets and determined that their carrying value exceeded their fair value. The fair value of these assets was measured employing cost and market approaches, using Level 3 inputs under ASC 820, Fair Value Measurement. Unobservable inputs included salvage value estimates, replacement or reproduction cost estimates, as well as consideration of physical deterioration, and functional and economic obsolescence, where measurable. As a result of this fair value analysis, an impairment charge of $2.2 million was recorded related to these long-lived assets in the quarter ended June 30, 2023. Subsequently, the Company sold these assets during the quarter ended September 30, 2023 at an amount that approximated carrying value after the impairment charges recorded.

In December 2022, the Company decided to cease further use and development of certain manufacturing machinery and equipment. The Company reviewed the recoverability of the carrying value of these assets and determined that their carrying value exceeded their fair value. The fair value of these assets was measured employing cost and market approaches, using Level 3 inputs under ASC 820, Fair Value Measurement.

Unobservable inputs included salvage value estimates, replacement or reproduction cost estimates as well as consideration of physical deterioration, functional and economic obsolescence, where measurable. As a result of this fair value analysis, an impairment charge of $4.2 million was recorded during the year ended December 31, 2022 related to these long-lived assets. Carrying value after the impairment charges approximates fair value.

Intangible Assets, Net - Summary of Intangible Assets with Definite and Indefinite Lives (Parenthetical) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Indefinite-Lived Intangible Assets [Line Items]
Tradename impairment	$ 2,169	$ 0
Trade Names [Member]
Indefinite-Lived Intangible Assets [Line Items]
Tradename impairment	$ 2,200

Income Taxes - Schedule of Net Deferred Tax Liability and Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax asset
Net operating loss carryforwards	$ 14,184	$ 8,005
Accrued compensation	803	552
Stock compensation	1,823	1,008
Tax credit carryforwards	880	275
Accruals and other	131	321
Operating lease liabilities	4,599	5,435
Capitalized research and development expenses	2,304	1,450
Inventory capitalization	428	0
Total deferred tax asset	25,152	17,046
Deferred tax liability
Property, plant, and equipment	(1,231)	(1,131)
Intangibles	(3,600)	(4,693)
Operating right-of-use lease assets	(4,402)	(5,275)
Total deferred tax liability	(9,233)	(11,099)
Valuation allowance	(16,838)	(7,170)
Net deferred tax liability	$ (919)	$ (1,223)

Long-Term Debt

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Long-Term Debt

Note 10. Long-Term Debt, Net

On May 10, 2022, the Company entered into the Amended and Restated Credit and Security Agreement (Term Loan) as borrower, with MidCap Financial Trust (MidCap), as agent and lender, and the additional lenders from time to time party thereto (the Term Loan Credit Agreement) and the Amended and Restated Credit and Security Agreement (Revolving Loan) as borrower, with MidCap as agent and lender, and the additional lenders from time to time party thereto (the Revolving Loan Credit Agreement, together with the Term Loan Credit Agreement, the Credit Agreement).

The Credit Agreement provided for a $57.135 million credit facility (the Credit Facility) consisting of a $52.135 million senior secured term loan (the Term Loan) and a $5.0 million working capital facility (the Revolver). The Term Loan consisted of the $12.0 million balance made available in 2021 under the previous credit facility and an additional $40.135 million, staged such that $5.135 million was funded upon closing of the Credit Agreement, an additional $5.0 million was funded on October 31, 2022, $10.0 million was to be available in the first half of 2023, $10.0 million was to be available in the second half of 2023 and $10.0 million was to be available in the first half of 2024, with the borrowing in the second half of 2023 and in the first half of 2024 being contingent upon achieving trailing twelve months of Clinical Solutions revenue of $15.0 million and $19.0 million, respectively, and liquidity requirements (as defined in the Credit Agreement) of $10.0 million and $15.0 million, respectively. The maximum loan amount under the Revolver was $5.0 million, and the Company was permitted to request the lenders to increase such amount up to $15.0 million. Borrowings on the Revolver were limited in accordance with a borrowing base calculation.

The interest on the Term Loan was based on the annual rate of one-month London Inter-Bank Offered Rate (LIBOR) plus 6.45%, subject to a LIBOR floor of 1.00%. If any advance under the Term Loan was prepaid at any time, the prepayment fee was based on the amount being prepaid and an applicable percentage amount, such as 3%, 2%, or 1%, based on the date the prepayment was made after the closing date of the Term Loan. Interest on the outstanding balance of the Revolver was payable monthly in arrears at an annual rate of one-month LIBOR plus 3.75%, subject to a LIBOR floor of 1.00%.

The maturity date of the Credit Facility is May 1, 2027. On the date of termination of the Term Loan or the date on which the obligations under the Term Loan become due and payable in full, the Company would pay an exit fee in an amount equal to 5.00% of the total aggregate principal amount of term loans made pursuant to the Term Loan as of such date. The Credit Agreement contained a financial covenant based upon a trailing twelve months of net revenue, including a requirement of $42.5 million in the twelve months ending December 31, 2022.

On November 8, 2022, the Company entered into Amendment No. 1 to the Credit Agreement (Amendment No. 1) which (i) replaced the LIBOR-based interest rate with a rate equal to the forward-looking one-month term Secured Overnight Financing Rate adjusted upward by 0.10% (or Term SOFR, as defined in Amendment No. 1) plus an applicable margin (6.45% for the Term Loan and 3.75% for the Revolver), with a Term SOFR floor of 1.00%, and with such interest rate calculation change taking effect on December 1, 2022, (ii) increased the applicable prepayment fee percentage amounts by one percentage point, (iii) gave the lenders discretion regarding the $10.0 million in borrowing that was previously guaranteed to be available under the Term Loan in the first half of 2023, and (iv) reduced the requirements for trailing twelve months of net revenue for all future periods. Concurrent with Amendment No. 1, the exit fee due on the date of termination of the Term Loan, or the date on which the obligations under the Term Loan become due and payable in full, increased from 5.00% to 7.00% of the total aggregate principal amount of term loans made pursuant to the Term Loan as of such date.

On March 28, 2023, the Company entered into Amendment No. 2 to the Credit Agreement (Amendment No. 2) which (i) increased the applicable margin from 6.45% to 7.00% for the Term Loan and from 3.75% to 4.00% for the Revolver, and increased the Term SOFR floor from 1.00% to 4.50% on both the Term Loan and Revolver, (ii) gave the lenders discretion regarding the $10.0 million in borrowings in the second half of 2023 and the $10.0 million in borrowings in the first half of 2024 by removing the trailing twelve-month Clinical Solutions revenue requirement that was previously required under the Term Loan, (iii) removed the increase in the minimum cash covenant from $10.0 million to $15.0 million on the $10.0 million in borrowings in the first half of 2024, and added the $10.0 million minimum cash covenant requirement throughout the remaining term of the Credit Agreement, and (iv) reduced the requirements for trailing twelve months of net revenue for all future periods—for example, for the twelve months ending December 31, 2023, the minimum net revenue requirement was reduced from $45.0 million to $42.0 million. Concurrent with Amendment No. 2, the exit fee due on the date of termination of the Term Loan, or the date on which the obligations under the Term Loan become due and payable in full, increased from 7.00% percent to 8.50% of the total aggregate principal amount of term loans made pursuant to the Term Loan as of such date.

On July 13, 2023, the Company entered into Amendment No. 3 to the Credit Agreement (Amendment No. 3), which amended the definition of Permitted Debt in the Credit Agreement from $250,000 to $1,100,000 to allow for the financing of the Company's D&O liability insurance and related policies as described further in Note 9. Accrued Liabilities.

On September 19, 2023, the Company entered into Amendment No. 4 to the Credit Agreement (Amendment No. 4). As previously disclosed in our Form 10-Q for the period ended June 30, 2023, the Company determined that it was not in compliance with the trailing twelve months minimum net revenue covenant contained in the Credit Agreement as of July 31, 2023. Amendment No. 4 includes a waiver from MidCap of the revenue covenant violation for the period ending July 31, 2023. As a condition to the effectiveness of Amendment No. 4, the Company prepaid the principal amount of the Term Loan in an amount equal to $10.0 million (the Term Loan Prepayment). The Company recognized a loss on the extinguishment of debt in the amount of $0.8 million related to the Term Loan Prepayment in the accompanying financial statements. Amendment No. 4 reduced the minimum net revenue requirements for future periods up to and including for the twelve months ending December 31, 2025—for example, the Company’s minimum net revenue requirement was reduced (i) for the twelve months ending December 31, 2023, from $42.0 million to $36.5 million, (ii) for the twelve months ending December 31, 2024, from $49.0 million to $42.0 million, and (iii) for the twelve months ending December 31, 2025, from $58.8 million to $50.0 million. Amendment No. 4 also removed those requirements for the periods ending January 31, 2026 through March 31, 2027, instead requiring that for each applicable twelve-month period ending after December 31, 2025, the Company’s minimum net revenue requirement was to be determined by MidCap in its reasonable discretion in consultation with the Company’s senior management and based on financial statements and projections delivered to MidCap in accordance with the financial reporting requirements in Amendment No. 4, so long as the minimum net revenue requirements for those periods shall not be less than the greater of (x) the applicable minimum net revenue requirement for the twelve-month period ending on the last day of the immediately preceding month and (y) $50.0 million. In addition, the minimum cash covenant requirement was reduced from $10.0 million to $9.0 million.

Concurrent with Amendment No. 4, the exit fee due on the date of termination of the Term Loan, or the date on which the obligations under the Term Loan become due and payable in full, increased from 8.5% to 9.0% of the total aggregate principal amount of term loans made pursuant to the Term Loan (including amendments thereto) as of such date. The Company did not pay a prepayment fee in connection with the Term Loan Prepayment. Finally, Amendment No. 4 conditioned the next borrowing under the Revolving Loan on the Company achieving net revenue for the preceding twelve-month period of at least $45.0 million.

Long-term debt, net consists of the following (in thousands):


	As of December 31,
	2023			2022
Long-term debt	$	12,135		$	22,135
Cumulative accretion of exit fee		1,261			161
Unamortized debt discount and debt issuance costs		(145	)		(320	)
Long-term debt, net	$	13,251		$	21,976

At December 31, 2023, the scheduled maturities of the Company's debt obligations were as follows (in thousands):


	Amount
2024	$	—
2025		3,539
2026		6,068
2027		2,528
Total	$	12,135

As of December 31, 2023, the fair value of the Company's long-term debt approximates its carrying value. The fair value of the Company's long-term debt was based on observable market inputs (Level 2).

Long-Term Debt - Summary of Components of Carrying Value of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Long term debt	$ 12,135	$ 22,135
Cumulative accretion of exit fee	1,261	161
Unamortized debt discount and debt issuance costs	(145)	(320)
Long-term debt, net	$ 13,251	$ 21,976

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Stock-Based Compensation - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Outstanding Beginning Balance	28,071
RSU, Granted	174,595
RSU, Vested	28,071
RSU, Forfeited	18,815
Number of Share, Outstanding Ending Balance	155,780	28,071
Number of Shares, Vested and expected to vest	155,780
Weighted Average Grant Date Fair Valu per Share, Outstanding Begning Balance	$ 7.43
Weighted Average Grant Date Fair Value per Share, Granted	4.93
Weighted Average Grant Date Fair Value per Share, Vested	7.43
Weighted Average Grant Date Fair Value per Share, Forfeited	3.93
Weighted Average Grant Date Fair Valu per Share, Outstanding Ending Balance	5.05	$ 7.43
Weighted Average Grant Date Fair Valu per Share, Vested and expected to vest	$ 5.05
Weighted Average Remaining Contractual Term, Outstanding	1 year 4 months 9 days	5 months 1 day
Weighted Average Remaining Contractual Term, Vested and expected to vest	1 year 4 months 9 days
Aggregate Intrinsic Value, Outstanding	$ 581	$ 158
Aggregate Intrinsic Value, Vested and expected to vest	$ 581

Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Teknova’s revenue, disaggregated by product category, was as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
Lab Essentials	$	28,800	$	31,772
Clinical Solutions		6,738		8,445
Other		1,146		1,203
Total revenue	$	36,684	$	41,420

Teknova’s revenue, disaggregated by geographic region, was as follows (in thousands):


	For the Year Ended December 31,
	2023		2022
United States	$	35,000	$	40,103
International		1,684		1,317
Total revenue	$	36,684	$	41,420

Other Financial Information (Tables)

12 Months Ended

Dec. 31, 2023

Income Statement [Abstract]

Schedule of change in the allowance for doubtful accounts

The change in the allowance for doubtful accounts is as follows:


	For the Year Ended December 31,
	2023			2022
Beginning balance	$	22		$	23
Provisions (benefits)		21			25
Recoveries (write-offs), net		(23	)		(26	)
Ending balance	$	20		$	22

Schedule of change in the inventory reserve

The change in the inventory reserve is as follows:


	For the Year Ended December 31,
	2023			2022
Beginning balance	$	1,046		$	470
Provisions (benefits)		323			697
Write-offs and other		(678	)		(121	)
Ending balance	$	691		$	1,046

Schedule of change in the income tax valuation allowance

The change in the income tax valuation allowance is as follows:


	For the Year Ended December 31,
	2023		2022
Beginning balance	$	7,170	$	477
Additions charged to expense		9,668		6,693
Reductions charged to other accounts		—		—
Ending balance	$	16,838	$	7,170

Summary of change in unrecognized tax benefits

The change in unrecognized tax benefits are as follows:


	For the Year Ended December 31,
	2023		2022
Beginning balance	$	42	$	—
Tax positions related to the current year:
Additions		86		42
Reductions		—		—
Tax positions related to the prior year:
Additions		8		—
Reductions		—		—
Ending balance	$	136	$	42

Leases

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Leases

Note 7. Leases

The Company leases office space, warehouse and manufacturing space, and equipment. The Company's lease agreements have remaining lease terms of one year to 14 years, and some of these leases have renewal and termination options exercisable at the Company’s election. Terms and conditions to extend or terminate such leases are recognized as part of the right-of-use assets and lease liabilities where reasonably certain to be exercised. All of the Company's leases are operating leases.

Operating lease expense was $2.9 million and $3.2 million for the years ended December 31, 2023 and 2022, respectively. Cash paid for amounts included in the measurement of the lease liabilities was $2.8 million in each of the years ended December 31, 2023 and 2022. The weighted-average discount rate was 5.0% and the weighted-average remaining lease term was 8.9 years as of December 31, 2023.

Maturities of operating lease liabilities at December 31, 2023, is as follows (in thousands):


	Amount
2024	$	2,601
2025		2,354
2026		2,413
2027		2,416
2028		2,265
Thereafter		9,652
Total lease payments		21,701
Less: imputed interest		(4,494	)
Present value of lease liabilities	$	17,207

Intangible Assets, Net

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

Note 8. Intangible Assets, Net

The following is a summary of intangible assets with definite and indefinite lives (in thousands):


	Balance at December 31, 2023						Balance at December 31, 2022
	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
Definite Lived:
Customer relationships	$	9,180	$	5,691	$	3,489	$	9,180	$	4,543	$	4,637
Indefinite Lived:
Tradename(1)		10,750		—		10,750		12,919		—		12,919
Total intangible assets	$	19,930	$	5,691	$	14,239	$	22,099	$	4,543	$	17,556

For each of the years ended December 31, 2023 and 2022 amortization expense was approximately $1.1 million.

The remaining weighted-average useful life of definite lived intangible assets is three years. The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands):


	Amount
2024	$	1,148
2025		1,148
2026		1,148
2027		45
Estimated future amortization expense of definite-lived intangible assets	$	3,489

In connection with the Company’s annual budgeting process, during the fourth quarter of 2023 the Company updated its 2024 budget to lower its financial projections in 2024 and beyond. Given the significance of the downward revisions to the Company’s forecast, primarily resulting from adverse industry and market conditions, an impairment test of Teknova’s indefinite lived tradename asset was performed as of December 31, 2023.

The fair value of the tradename was determined using the relief from royalty method. Significant assumptions under this method include forecasted revenues, royalty rate, discount rate, and terminal value. Fair values were determined using Level 3 inputs under ASC 820, Fair Value Measurement (ASC 820). Based on the impairment test performed, the Company determined that the Teknova tradename was impaired as of December 31, 2023. As a result, the Company recognized a $2.2 million non-cash impairment charge for the Teknova tradename during the fourth quarter ended December 31, 2023. The impairment charge represented the difference between the estimated fair value of the Company’s tradename and its carrying value. The carrying value of the indefinite lived tradename asset as of December 31, 2023 was $10.8 million. There was no impairment of the indefinite lived tradename asset during the year ended December 31, 2022.

There was no impairment of definite lived intangible assets during the years ended December 31, 2023 and 2022.

During the year ended December 31, 2022 the Company recorded a $16.6 million impairment charge related to goodwill. During the three months ended September 30, 2022, the market price of Teknova’s common stock and market capitalization declined significantly. Given the significance of this decline, the Company performed interim goodwill impairment testing.

The fair value of the Company was determined using a combination of an income approach and market approach. The income approach was based on the present value of future cash flows, which were derived from financial forecasts, and requires significant assumptions and judgment including, among others, a discount rate and a terminal value. Fair values were based on expected future cash flows using Level 3 inputs under ASC 820. The cash flows are those expected to be generated by the Company, discounted at the weighted average cost of capital. The present value of future cash flows was determined by discounting estimated future cash flows at an 18.0% weighted average cost of capital, which considers the risk of achieving the projected cash flows, long-term growth rate, the risk applicable to the Company, industry, and to the market as a whole.

The guideline public company method, a market approach method, was also used to estimate the fair value of the Company. The guideline public company method utilizes the trading multiples of similarly traded public companies. The unobservable inputs used to measure the fair value primarily included projected revenue growth rates and the determination of appropriate market comparison companies. Selected multiples were considered and applied to the trailing-twelve-month and next-twelve-month enterprise value-to-revenue multiples.

The resulting estimated fair value was reconciled to the Company’s market capitalization. The reconciliation included an estimated implied control premium above the Company's market capitalization on September 30, 2022, of approximately 25%. Based on the results of the impairment test, the Company determined goodwill was fully

impaired as of December 31, 2022.

Contingencies

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Contingencies

Note 16. Contingencies

From time to time, we may become involved in lawsuits and other claims arising from our ordinary course of business. The Company regularly evaluates its exposure to threatened or pending litigation and other business contingencies. Because of the uncertainties related to the amount of loss from litigation and other business contingencies, the recording of losses relating to such exposures requires significant judgment about the potential range of outcomes. We establish loss provisions for matters in which losses are probable and can be reasonably estimated. If a loss is not both probable and reasonably estimable, or if an exposure to loss exists in excess of the amount accrued, the Company assesses whether there is at least a reasonable possibility that a loss, or additional loss, may have been incurred. If there is a reasonable possibility that a loss, or additional loss, may have been incurred, the Company will disclose the estimate of the possible loss or range of loss if it is material and an estimate can be made, or disclose that such an estimate cannot be made. The determination as to whether a loss can reasonably be considered to be possible or probable is based on our assessment, together with legal counsel, regarding the ultimate outcome of the matter. As additional information about current or future litigation or other contingencies becomes available, the Company will assess whether adjustments should be made to legal accruals.

In August 2023, a former Teknova employee filed a claim with the Labor and Workforce Development Agency alleging various causes of action under California’s labor, wage, and hour laws. The plaintiff generally alleges that Teknova did not appropriately calculate and pay meal break premiums and otherwise failed to calculate and pay appropriate overtime wages or bonuses to certain of its California non-exempt employees. A mediation has been scheduled for June 6, 2024. As of December 31, 2023, the Company has accrued its best estimate of potential loss related to a possible settlement of the claims of the former employee and other employees who may assert similar claims, in the amount of $0.3 million, which is included within “Accrued liabilities” on the Balance Sheet. The actual loss attributable to the final resolution of this and related claims could differ materially from the Company’s present best estimate.

Inventories, Net - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods, net	$ 8,573	$ 8,368
Work in process	47	186
Raw materials, net	2,974	3,693
Total inventories, net	$ 11,594	$ 12,247

Income Taxes - Summary of Reconciliation of the Statutory Tax Rate to the Company's Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Statutory federal income tax rate%	21.00%	21.00%
State income tax rate	5.90%	5.60%
Stock compensation	(0.50%)	(0.50%)
Research and development credit	0.70%	0.20%
Change in valuation allowance	(26.10%)	(13.60%)
Goodwill impairment	0.00%	(9.00%)
Other	(0.20%)	0.20%
Effective tax rate %	0.80%	3.90%

Summary of Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Summary of Estimated Useful Lives of Major Classes of Property and Equipment

The estimated useful lives of the major classes of property and equipment are as follows:


		Estimated Useful Lives
Machinery and equipment		5 – 15 years
Office furniture and equipment		3 – 7 years
Vehicles		5 years
Leasehold improvements		3 – 15 years

Revenue Recognition - Additional Information (Details)	12 Months Ended
Revenue Recognition - Additional Information (Details)	Dec. 31, 2023 ProductLines
Revenue from Contract with Customer [Abstract]
Number of product categories	2

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Schedule of Provision for Income Tax Expense (Benefit)

Teknova’s benefit from income taxes consist of the following (in thousands):


	For the Year Ended December 31,
	2023			2022
Current:
Federal	$	—		$	—
State		6			7
Total current		6			7
Deferred:
Federal		(25	)		(2,055	)
State		(279	)		125
Total deferred		(304	)		(1,930	)
Income tax benefit	$	(298	)	$	(1,923	)

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the statutory tax rate to the Company’s effective tax rate is as follows:


	For the Year Ended December 31,
	2023			2022
Statutory federal income tax rate %		21.0	%		21.0	%
State income tax rate		5.9			5.6
Stock compensation		(0.5	)		(0.5	)
Research and development credit		0.7			0.2
Change in valuation allowance		(26.1	)		(13.6	)
Goodwill impairment		—			(9.0	)
Other		(0.2	)		0.2
Effective tax rate %		0.8	%		3.9	%

Schedule of Net Deferred Tax Liability and Assets

The Company’s component of net deferred tax liability and assets consist of the following (in thousands):


	As of December 31,
	2023			2022
Deferred tax asset
Net operating loss carryforwards	$	14,184		$	8,005
Accrued compensation		803			552
Stock compensation		1,823			1,008
Tax credit carryforwards		880			275
Accruals and other		131			321
Operating lease liabilities		4,599			5,435
Capitalized research and development expenses		2,304			1,450
Inventory capitalization		428			—
Total deferred tax asset		25,152			17,046
Deferred tax liability
Property, plant, and equipment		(1,231	)		(1,131	)
Intangibles		(3,600	)		(4,693	)
Operating right-of-use lease assets		(4,402	)		(5,275	)
Total deferred tax liability		(9,233	)		(11,099	)
Valuation allowance		(16,838	)		(7,170	)
Net deferred tax liability	$	(919	)	$	(1,223	)

Nature of the Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Sep. 15, 2023	Dec. 31, 2023	Dec. 31, 2022
Subsidiary Sale Of Stock [Line Items]
Offering expenses		$ 400
Common stock, par value		$ 0.00001	$ 0.00001
Proceeds from equity financing, net	$ 22,915	$ 22,503	$ 0
PIPE Purchase Agreement [Member]
Subsidiary Sale Of Stock [Line Items]
Common stock, par value	$ 0.00001
Issuance of common stock upon initial public offering, net of issuance costs and underwriting discounts	11,299,993
Shares Issued	$ 1.85
Shares issued to related parties	9,054,052
Registered Direct Purchase Agreement [Member]
Subsidiary Sale Of Stock [Line Items]
Issuance of common stock upon initial public offering, net of issuance costs and underwriting discounts	1,086,485
Shares Issued	$ 1.85

Accrued Liabilities

12 Months Ended

Dec. 31, 2023

Accrued Liabilities, Current [Abstract]

Accrued Liabilities

Note 9. Accrued Liabilities

Accrued liabilities were comprised of the following (in thousands):


	As of December 31,
	2023		2022
Payroll-related	$	3,826	$	2,796
Property, plant, and equipment		—		1,966
Deferred revenue		16		198
Insurance premiums and accrued interest		409		—
Loss contingency accrual		300		—
Other		1,028		1,243
Total current accrued liabilities	$	5,579	$	6,203

On July 13, 2023, the Company entered into a financing agreement with First Insurance Funding for the financing of the Company's Directors and Officers (D&O) liability insurance and related policies. Under the terms of the financing agreement, the Company agreed to pay a total of $1.2 million in premiums, taxes and fees, plus interest at an annual percentage rate of 7.74% in ten monthly installment payments commencing on July 25, 2023. During the year ended December 31, 2023, the Company paid a down payment on the policy of $0.2 million to the insurer and an aggregate of $0.6 million in monthly installments to First Insurance Funding. As of December 31, 2023, the Company owed $0.4 million for insurance premiums and accrued interest.